Health, EFSA. P. O. A., (AHAW), W., More, S., Bøtner, A., Butterworth, A., Calistri, P., ... Bicout, D. (2017). Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus disease. *EFSA Journal, 15*(7), [e04890].
https://doi.org/10.2903/j.efsa.2017.4890
Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus disease

EFSA Panel on Animal Health and Welfare (AHAW),
Simon More, Anette Bøtner, Andrew Butterworth, Paolo Calistri, Klaus Depner,
Sandra Edwards, Bruno Garin-Bastuji, Margaret Good, Christian Gortázar Schmidt,
Virginie Michel, Miguel Angel Miranda, Søren Saxmose Nielsen, Mohan Raj, Liisa Sihvonen,
Hans Spoolder, Jan Arend Stegeman, Hans-Hermann Thulke, Antonio Velarde,
Preben Willeberg, Christoph Winckler, Francesca Baldinelli, Alessandro Broglio,
Beatriz Beltrán Beck, Lisa Kohnle, Joana Morgado and Dominique Bicout

Abstract

Ebola virus disease has been assessed according to the criteria of the Animal Health Law (AHL), in particular criteria of Article 7 on disease profile and impacts, Article 5 on the eligibility of Ebola virus disease to be listed, Article 9 for the categorisation of Ebola virus disease according to disease prevention and control rules as in Annex IV and Article 8 on the list of animal species related to Ebola virus disease. The assessment has been performed following a methodology composed of information collection and compilation, expert judgement on each criterion at individual and, if no consensus was reached before, also at collective level. The output is composed of the categorical answer, and for the questions where no consensus was reached, the different supporting views are reported. Details on the methodology used for this assessment are explained in a separate opinion. According to the assessment performed, Ebola virus disease can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL. The disease would comply with the criteria as in Sections 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in points (d) and (e) of Article 9(1). The animal species to be listed for Ebola virus disease according to Article 8(3) criteria are some species of non-human primates, pigs and rodents as susceptible species and some species of fruit bats as reservoir, as indicated in the present opinion.

© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Keywords: Ebola virus disease, Animal Health Law, listing, categorisation, impact

Requestor: European Commission
Question number: EFSA-Q-2016-00602
Correspondence: alpha@efs.europa.eu
Panl on Animal Health and Welfare (AHAW) members: Dominique Bicout, Anette Bøtner, Andrew Butterworth, Paolo Calistri, Klaus Depner, Sandra Edwards, Bruno Garin-Bastuji, Margaret Good, Christian Gortazar Schmidt, Virginie Michel, Miguel Angel Miranda, Simon More, Søren Saxmose Nielsen, Mohan Raj, Liisa Sihvonen, Hans Spoolder, Jan Arend Stegeman, Hans-Hermann Thulke, Antonio Velarde, Preben Willeberg, Christoph Winckler.

Acknowledgements: The AHAW Panel wishes to thank Siv Aina Leendertz and Fabian Leendertz for the support provided to this scientific output.

Suggested citation: EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare), More S, Bøtner A, Butterworth A, Calistri P, Depner K, Edwards S, Garin-Bastuji B, Good M, Gortazar Schmidt C, Michel V, Miranda MA, Nielsen SS, Raj M, Sihvonen L, Spoolder H, Stegeman JA, Thulke H-H, Velarde A, Willeberg P, Winckler C, Baldinelli F, Broglia A, Beltrán Beck B, Kohnle L, Morgado J and Bicout D, 2017. Scientific Opinion on the assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus disease. EFSA Journal 2017;15(7):4890, 37 pp. https://doi.org/10.2903/j.efsa.2017.4890

ISSN: 1831-4732

© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.
Table of contents

Abstract................................................................................................................................................... 1
1. Introduction........................................................................................................................................ 4
1.1. Background and Terms of Reference as provided by the requestor................................. 4
1.2. Interpretation of the Terms of Reference.................................................................................. 4
2. Data and methodologies...................................................................................................................... 4
3. Assessment........................................................................................................................................ 4
3.1. Assessment according to Article 7 criteria.................................................................................. 4
3.1.1. Article 7(a) Disease Profile...................................................................................................... 4
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease.................................................... 4
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal populations........ 6
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease......................................................... 8
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance.............. 8
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the environment..... 9
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between animals, and, when relevant, between animals and humans................................................................. 10
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the Union, and, where the disease is not present in the Union, the risk of its introduction into the Union...................... 11
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools.............................. 13
3.1.2. Article 7(b) The impact of diseases............................................................................................ 14
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture production and other parts of the economy ........................................................................................................ 14
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health..................................................... 14
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare................................................. 15
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment..................... 15
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use in bioterrorism.... 16
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following disease prevention and control measures .................................................................................................................................. 16
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities........................................................................... 16
3.1.4.2. Article 7(d)(ii) Vaccination....................................................................................................... 17
3.1.4.3. Article 7(d)(iii) Medical treatments.......................................................................................... 17
3.1.4.4. Article 7(d)(iv) Biosecurity measures....................................................................................... 18
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products............................... 19
3.1.4.6. Article 7(d)(vi) Killing of animals.............................................................................................. 20
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products.................... 20
3.1.5. Article 7(e) The impact of disease prevention and control measures.................................... 20
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the economy as a whole... 20
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control measures .......... 20
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals............... 21
3.1.5.4. Article 7(e)(iv) The environment and biodiversity................................................................. 21
3.2. Assessment according to Article 5 criteria ................................................................................. 21
3.2.1. Outcome of the assessment of Ebola virus disease according to criteria of Article 5(3) of the AHL on its eligibility to be listed ........................................................................................................ 22
3.3. Assessment according to Article 9 criteria................................................................................... 22
3.3.1. Non-consensus questions.......................................................................................................... 24
3.3.2. Outcome of the assessment of criteria in Annex IV for Ebola virus disease for the purpose of categorisation as in Article 9 of the AHL........................................................................... 27
3.4. Assessment of Article 8............................................................................................................... 28
4. Conclusions....................................................................................................................................... 29
References.............................................................................................................................................. 29
Abbreviations......................................................................................................................................... 37
1. Introduction

1.1. Background and Terms of Reference as provided by the requestor

The background and Terms of Reference (ToR) as provided by the European Commission for the present document are reported in Section 1.2 of the scientific opinion on the ad hoc methodology followed for the assessment of the disease to be listed and categorised according to the criteria of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA AHAW Panel, 2017).

1.2. Interpretation of the Terms of Reference

The interpretation of the ToR is as in Section 1.2 of the scientific opinion on the ad hoc methodology followed for the assessment of the disease to be listed and categorised according to the criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW Panel, 2017).

The present document reports the results of assessment on Ebola virus disease according to the criteria of the AHL articles as follows:

- Article 7: Ebola virus disease profile and impacts
- Article 5: eligibility of Ebola virus disease to be listed
- Article 9: categorisation of Ebola virus disease according to disease prevention and control rules as in Annex IV
- Article 8: list of animal species related to Ebola virus disease.

2. Data and methodologies

The methodology applied in this opinion is described in detail in a dedicated document about the ad hoc method developed for assessing any animal disease for the listing and categorisation of diseases within the AHL framework (EFSA AHAW Panel, 2017).

3. Assessment

3.1. Assessment according to Article 7 criteria

This section presents the assessment of Ebola virus disease according to the Article 7 criteria of the AHL and related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on the information contained in the fact-sheet as drafted by the selected disease scientist (see section 2.1 of the scientific opinion on the ad hoc methodology) and amended by the AHAW Panel.

3.1.1. Article 7(a) Disease Profile

Ebola virus (EV) disease (previously known as Ebola haemorrhagic fever) is a zoonotic disease of major concern for human health and certain African wildlife. The disease is caused by four of the five recognised species of the genus *Ebola*: *Ebolavirus* (formerly known as *Zaire ebolavirus*), *Sudan ebolavirus*, *Bundibugyo ebolavirus* and *Tai Forest ebolavirus* (Feldmann and Geisbert, 2011; Rougeron et al., 2015; CDC, online-e; WHO, online-f).

3.1.1.1. Article 7(a)(i) Animal species concerned by the disease

**Susceptible animal species**

Parameter 1 – Naturally susceptible wildlife species (or family/orders)

Species that develop viral haemorrhagic fever, in which the virus has been isolated:

- Western gorilla (*Gorilla gorilla*) (Leroy et al., 2004a; Rouquet et al., 2005; Wittmann et al., 2007; Reed et al., 2014)
- Chimpanzee (*Pan troglodytes*) (Georges-Courbot et al., 1997a; Formenty et al., 1999; Georges et al., 1999; Leroy et al., 2004a; Rouquet et al., 2005; Wittmann et al., 2007)
- Bay duiker (*Cephalophus dorsalis*) (Rouquet et al., 2005)
Species with asymptomatic infection, in which viral nucleic acids have been detected:

- Franquet's epauletted fruit bat (*Epomops franqueti*) (Leroy et al., 2005; Pourrut et al., 2007, 2009; Hayman et al., 2012)
- Hammer-headed fruit bat (*Hypsiprymnodon monstrosus*) (Leroy et al., 2005; Pourrut et al., 2007, 2009; Hayman et al., 2012)
- Little collared fruitbat (*Myonycteris torquata*) (Leroy et al., 2005; Pourrut et al., 2007, 2009)
- Peters’ mouse (*Mus setulosus*) (Morvan et al., 1999)
- *Praomys* spp. (Morvan et al., 1999)
- Greater forest shrew (*Sylvisorex ollula*) (Morvan et al., 1999)

Species with asymptomatic infection, in which antibodies have been detected (WHO, online-f):

- Egyptian fruit bat (*Rousettus aegyptiacus*) (Pourrut et al., 2009)
- Leschenault's rousette (*Rousettus leschenaultii*) (Olival et al., 2013)
- Gambian epauletted fruit bat (*Epomophorus gambianus*) (Hayman et al., 2012)
- African straw-coloured fruit bat (*Eidolon helvum*) (Hayman et al., 2010; Ogawa et al., 2015)
- Peter’s lesser epauletted fruit bat (*Micropteropus pusillus*) (Pourrut et al., 2009)
- Angolan free-tailed bat (*Mops condylura*) (Pourrut et al., 2009)

Species of captive, wild-born animals that have been exposed to the virus with unknown history of symptoms and in which antibodies have been detected:

- Mandrill (*Mandrillus sphinx*) (Leroy et al., 2004b)
- Drill (*Mandrillus leucophaeus*) (Leroy et al., 2004b)
- Olive baboon (*Papio Anubis*) (Leroy et al., 2004b)
- De Brazza’s monkey (*Cercopithecus neglectus*) (Leroy et al., 2004b)

Full host range is not known. Observed mortality in other wildlife indicates that additional species might be susceptible to Ebola, e.g. among the mandrills (*Mandrillus* sp.), guenon (*Cercopithecus* sp.) and other nonhuman primates, as well as forest antelopes (*Cephalophus* sp.), bush pigs (*Potamochoerus porcus*), brush-tailed porcupines (*Atherurus africanus*) and other species (Lahm et al., 2007; Olson et al., 2012; Olivero et al., 2017).

Parameter 2 – Naturally susceptible domestic species (or family/orders)

Species that have been exposed to the virus with unknown history of symptoms and from which antibodies have been detected:

- Dogs (Allela et al., 2005; WHO, online-f)
- Guinea pigs (Stansfield et al., 1982)

Parameter 3 – Experimentally susceptible wildlife species (or family/orders)

Susceptible species that develop viral haemorrhagic fever:

- Rhesus macaques (*Macaca mulatta*) (Geisbert et al., 2015)
- Cynomolgus macaques (*Macaca fascicularis*) (Geisbert et al., 2015)
- Marmosets (*Callithrix jacchus*) (Smither et al., 2015)
- Baboon (*Papio spp.*) (Perry et al., 2012)
- African green monkeys (*Cercopithecus aethiops*) (Davis et al., 1997)
- Vervet monkey (*Chlorocebus pygerythrus*) (Bowen et al., 1978)

Susceptible species that develop asymptomatic infection, in which nucleic acids were detected and seroconverted (WHO, online-f):

- Egyptian rousette fruit bat (*Rousettus aegyptiacus*) (Jones et al., 2015; Paweska et al., 2016)
- Wahlberg's epauletted fruit bat (*Epomophorus wahlbergi*) (Swanepoel et al., 1996)
- Angolan free-tailed bat (*Mops condylura*) (Swanepoel et al., 1996)
- Little free-tailed bat (*Tadarida pumila*, i.e. *Chaerephon pumilus*) (Swanepoel et al., 1996)

Species susceptible to species-adapted strains only (WHO, online-f):

- Mice (Banadyga et al., 2016; Cheresiz et al., 2016)
- Syrian hamster (*Mesocricetus auratus*) (Wahl-Jensen et al., 2012; Ebihara et al., 2013)
Parameter 4 – Experimentally susceptible domestic species (or family/orders)

Species that develop viral haemorrhagic fever:
- Domestic ferret (*Mustela putorius furo*) (Cross et al., 2016; Kozak et al., 2016)

Species that develop respiratory disease symptoms:
- Pigs (Kobinger et al., 2011; Weingartl et al., 2012)

Species susceptible to species-adapted strains only4:
- Guinea pigs (Banadyga et al., 2016; Cheresiz et al., 2016)

Species insensitive to infection, no detection of virus nucleic acid but seroconverted (animals purposely inoculated to produce hyperimmune serum):
- Goats (Dedkova, 1993; Kudoyarova-Zubavichene et al., 1999)
- Sheep (Dedkova, 1993; Kudoyarova-Zubavichene et al., 1999)
- Horses (Krasnianskii et al., 1995; Zheng et al., 2016)

Parameter 5 – Wild reservoir species (or family/orders)

This is not fully understood, but fruit bats have long been suspected to be reservoir species because: (1) studies have shown asymptomatic infections in the wild and in experimental studies, (2) 13 wild caught specimens have harboured viral nucleic acid, (3) antibodies have been detected in several species, and (4) contact to bats have been suspected to be the origin of human epidemics in West Africa, Democratic Republic of Congo and Sudan (WHO, 1978; Baron et al., 1983; Leroy et al., 2005; Pourrut et al., 2007; Leroy et al., 2009; Pourrut et al., 2009; Hayman et al., 2010, 2012; Olival et al., 2013; Mari Saéz et al., 2015; Ogawa et al., 2015).

However, natural shedding of the virus has not been reported and the virus has not been isolated from wild bats. The suspected links between bats and human outbreaks have not been confirmed and further research is necessary to confirm or identify reservoir species. Great apes (family Hominidae, e.g. chimpanzees and gorillas) are not considered reservoirs given the disease's rapid spread and high case fatality in these species, i.e. they do not fulfill important criteria for a reservoir host (Huibregts et al., 2003; Olival and Hayman, 2014; Leendertz et al., 2016).

The susceptibility of Barbary macaque, bat and monkey species present in the European Union (EU) overseas territory is not known.

Parameter 6 – Domestic reservoir species (or family/orders)

There are no species recognised so far.

3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal populations

Morbidity

Parameter 1 – Prevalence/Incidence

See Table 1.

Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)

The case-morbidity rate is unknown.
**Mortality**

**Parameter 3 – Case-fatality rate**

**Table 1:** Seroprevalence and mortality in Ebola-infected animal populations. There are no data on the case-morbidity rate (% clinically diseased animals out of infected ones)

| Species (references) | Seroprevalence (% (n samples)) | Mortality | Country | Time period |
|----------------------|--------------------------------|-----------|---------|------------|
| Bats (Leroy et al., 2005; Pourrut et al., 2007, 2009; Hayman et al., 2010, 2012; Olival et al., 2013; Ogawa et al., 2015) | | | | |
| Franquet's epauletted fruit bat (*Epomops franqueti*) | | | | |
| None | None | None | Gabon | 2004 |
| 3.9 (355) | None | None | Gabon/ROC | 2003–2005 |
| 1.4 (370) | None | None | Gabon/ROC | 2006 |
| 4 (805) | None | None | Gabon/ROC | 2003–2008 |
| 11 (27) | None | None | Gabon/ROC | 2008 |
| Hammer-headed fruit bat (*Hypsignathus monstrosus*) | | | | |
| 24 (17) | None | None | Gabon | 2001–2003 |
| 5.6 (67) | None | None | Gabon/ROC | 2003–2005 |
| 2.2 (44) | None | None | Gabon/ROC | 2006 |
| 7 (125) | None | None | Gabon/ROC | 2003–2008 |
| 12.5 (16) | None | None | Ghana | 2008 |
| Little collared fruit bat (*Myonycteris torquata*) | | | | |
| 7 (54) | None | None | Gabon | 2001–2003 |
| 3.9 (231) | None | None | Gabon/ROC | 2003–2005 |
| 0.3 (323) | None | None | Gabon/ROC | 2006 |
| 3 (573) | None | None | Gabon/ROC | 2003–2008 |
| Egyptian rousette (*Rousettus aegyptiacus*) | | | | |
| 8 (307) | None | None | Gabon/ROC | 2003–2008 |
| Leschenault's rousette (*Rousettus leschenaultii*) | | | | |
| 3.5 (37) | None | None | Bangladesh | 2010–2011 |
| Gambian epauletted fruit bat (*Epomorphus gambianus*) | | | | |
| 11 (37) | None | None | Ghana | 2008 |
| African straw-coloured fruit bat (*Eidolon helvum*) | | | | |
| 1 positive specimen (262) | None | None | Ghana | 2008–2009 |
| 9.5 (748) | None | None | Gabon | 2008–2009 |
| Peter’s lesser epauletted fruit bat (*Micropteropus pusillus*) | | | | |
| 2 (197) | None | None | Gabon/ROC | 2003–2008 |
| Insectivorous bats incl. Angolan free-tailed bat (*Mops condylurus*) and Giant Leaf-nosed Bat (*Hipposideros gigas*) | | | | |
| 12 (24) | None | None | Gabon/ROC | 2003–2008 |
| Rodents/Shrew (Morvan et al., 1999) | | | | |
| Peters mouse (*Mus setulosus*) | 4 PCR positive | None | CAR | Not reported |
| *Praomys spp.* | 2 PCR positive | None | CAR | Not reported |
| Greater forest shrew (*Sylvirexella allula*) | 1 PCR positive | None | CAR | Not reported |
| Primates (Formenty et al., 1999; Leroy et al., 2004a; Rouquet et al., 2005; Wittmann et al., 2007; Reed et al., 2014) | | | | |
| Western gorilla (*Gorilla gorilla*) | Not estimated | Population declines up to 98% | Gabon/ROC | 1994–1996 |
| Not estimated | Population declines up to 98% | Gabon/ROC | 2000–2006 |
| 10 (80) | (no outbreak) | ROC | 2005–2007 |
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease

**Presence**

Zoonotic human infections have been reported in several African countries (Pigott et al., 2014; CDC, online-f). In most cases, the zoonotic origin of infection is still unknown.

Infections have been reported in Democratic Republic of Congo in 1972, 1976, 1977, 1995, 2007, 2008, 2012 and 2014. In 2007, the index case was a child who had presumably been infected through the sweat of her asymptomatic father who had bought fruit bat meat at the local market (Leroy et al., 2009); however, none of the numerous hunters who took part in the large annual mass hunting of the bats were among the first to succumb to the disease and it has been questioned if fruit bats were indeed the origin of the outbreak (Leendertz et al., 2016). In 2014, the index case was a woman who had been in contact with a non-human primates (NHP) carcass (unidentified species); however, no samples were obtained for confirmation of Ebola virus infection in the carcass (Maganga et al., 2014). No source of infection was suspected in the other outbreaks.

All outbreaks in Gabon (1994, January and July 1996, 2001) and Republic of Congo (2000, 2001, 2002, 2003, 2005) were epidemiologically linked with infected gorillas, chimpanzees and duikers through hunting or scavenging; the source of three of these outbreaks were also laboratory confirmed (Georges-Courbot et al., 1997b; Georges et al., 1999; Rouquet et al., 2005).

In Côte d’Ivoire in 1994, one researcher was infected when performing a necropsy on an infected chimpanzee carcass (Formenty et al., 1999).

In Sudan in 1976 and 1979, the outbreaks were epidemiologically linked to a cotton factory where insectivorous bats were roosting; in the outbreak in 2004 no such link was suspected (WHO, 1978; Baron et al., 1983).

In Guinea in 2013, the index case was a 2-year-old child who had likely been in direct or indirect contact with a large colony of insectivorous bat (Mops condylurus) roosting in a hollow tree, however, this link was not confirmed (Mari Saéz et al., 2015).

No infectious source could be identified in the outbreaks in Uganda in 2000, 2007, 2011 and May and November 2012.

Serological surveys indicate that contacts with the virus outside outbreak times have occurred (Heymann et al., 1980; Mathiot et al., 1989; Becquart et al., 2010; Schoepf et al., 2014; Mulangu et al., 2016).

3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance

Parameter 1 – Resistant strain to any treatment even at laboratory level

No treatment is licensed for human or animal use (please see section below).
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the environment

Animal population

Parameter 1 – Duration of infectious period in animals

Bats: Not known. Viral nucleic acid has been detected but the virus has not been isolated from wild bats (Leroy et al., 2005; Pourrut et al., 2007, 2009; Hayman et al., 2010, 2012; Olival et al., 2013; Ogawa et al., 2015). In one experimental study of the insectivorous bats species *Mops condylurus* and *Chaerephon pumilus* and the fruit bat species *Epomophorus wahlbergi*, the virus was isolated in blood and tissue up to 3 weeks post infection and in one of the infected fruit bats the virus was also isolated once from faeces (Swanepoel et al., 1996) indicating that the infectious period in susceptible bat species may be more than 3 weeks, although no natural shedding of Ebola has been detected (Kuhn, 2008; Olival and Hayman, 2014; Schoepp et al., 2014).

Non-human primates (NHP): The biological aspects of the disease process are similar in humans and NHP and individuals are currently presumed infectious when clinical symptoms occur (Kuhn, 2008; Olival and Hayman, 2014; Schoepp et al., 2014). Experimental infections show that death in NHPs usually occur ca. 5-8 days post-infection but can occur up to 14 days after infection depending on dose and species of virus (Geisbert et al., 2009; Nakayama and Saijo, 2013). Filoviruses could be isolated up to 20 days after onset of infection from surviving NHPs (Fisher-Hoch et al., 1992).

One study reported ape carcasses remaining infectious in the rainforest for 3-4 days; another determined the virus to remain viable up to 7 days in macaque carcasses (Leroy et al., 2004a; Prescott et al., 2015).

The virus is not inactivated by freezing or refrigeration (Chepurnov et al., 1995; Piercy et al., 2010). It is uncertain how long EV survives in carcasses and meat under different environmental conditions, e.g. salting and drying (EFSA, 2014, 2015b).

Parameter 2 – Presence and duration of latent infection period

The occurrence of latent infection is not known in bats nor in chimpanzees and gorillas.

Parameter 3 – Presence and duration of the pathogen in healthy carriers

The infection is asymptomatic in bats. Studies of wild bats caught 5 months apart in a human outbreak area showed rapid clearance of the infection (Leroy et al., 2005). The virus could be recovered up to 3 weeks in experimentally infected, asymptomatic bats (Swanepoel et al., 1996).

Semen from men who survived the infection may remain infectious for 179 days or more after onset of symptoms (Mate et al., 2015); such viral persistence may also occur in healthy great apes (Leendertz et al., 2017). In one case, EV genetic material could be detected after 565 days but the test could not tell if live virus was present and capable of spreading disease (Soka et al., 2016).

Environment

Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil, water, air) from the environment (scenarios: high and low T)

Data exist only from experiments which are usually mimicking hospital settings and are not based on observations in nature.

Table 2: Ebola-virus survival in the environment

| Environment         | Survival       | Temp. (°C) | Rel. humidity (%) | Additional conditions | Ref.        |
|---------------------|----------------|------------|-------------------|-----------------------|-------------|
| Blood               | Up to 14 days  | 21 or 27   | 40 or 80          |                       | (Fischer et al., 2015) |
| Drying blood        | Up to 5 days   | 21         | 40                 |                       | (Fischer et al., 2015) |
| Drying blood        | Up to 5 days   | 27         | 80                 |                       | (Fischer et al., 2015) |
| Serum               | Up to 46 days  | 4 or 24    | 50–55              |                       | (Wittmann et al., 2007) |
| Semen               | At least 8 days| 27         | 80                 |                       | (Fischer et al., 2016b) |
| Dried semen         | Up to 4 days   | 27         | 80                 |                       | (Fischer et al., 2016b) |
| On solid surface    | Up to 6 days   | 21         | 40                 | In darkness           | (Sagripanti et al., 2010) |
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between animals, and, when relevant, between animals and humans

Routes of transmission

Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)

Transmission chains and routes are not known for most animals.

NHP-to-NHP transmission: Horizontal transmission. Direct contact, conjunctival and oral contact with infected individuals, carcasses and body fluids (Feldmann and Geisbert, 2011; Mire et al., 2016). Transmission via sexual contact with surviving males is theoretically possible as this route has been identified in humans (Mate et al., 2015). It is not known how the infection enters into the NHP population (Leendertz et al., 2017).

Bat-to-bat transmission: Such transmission is not confirmed. Virus has not been isolated from wild bats and virus shedding in wild bats has not been detected (Leroy et al., 2005; Pourrut et al., 2007, 2009; Hayman et al., 2010, 2012; Olival et al., 2013; Olival and Hayman, 2014; Ogawa et al., 2015). Experimentally infected bats (Rousettus aegyptiacus) did not infect other in-contact bats of the same species (Paweska et al., 2016).

Aerosol transmission in laboratory settings:

Experimental aerosol infection documented in NHP, pigs, mice, and guinea pigs (Johnson et al., 1995; Kobinger et al., 2011; Reed et al., 2011; Weingartl et al., 2012; Zumbrun et al., 2012a,b; Twenhafel et al., 2013, 2015; Smither et al., 2015).

Aerosol transmission reported from guinea pigs to guinea pigs, pigs to pigs, pigs to NHP and from NHP to NHP (Dedkova, 1993; Jaax et al., 1995; Kobinger et al., 2011; Weingartl et al., 2012; Wong et al., 2015).

In these experiments, the animals were housed close together and droplet infection cannot be excluded. Filoviruses have very little or no capacity to be airborne, i.e. no inhalation of infectious particles takes place at a distance from the source. Transmission by air is not similar to influenza or other airborne infection and the virus does not transmit from an infected person to a susceptible person that is located at a distance (Mekibib and Ariën, 2016).

Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including food-borne)

Direct contact via hunting, scavenging or butchering of infected NHP or other infected wildlife. There is epidemiological evidence of such transmission in the human outbreaks in Gabon and Republic of Congo in 1994 and 1996 and 2000–2005; three outbreaks were also laboratory confirmed by isolation of virus in carcasses from gorillas, chimpanzees and duiker (Georges et al., 1999; Rouquet et al., 2005; Nkoghe et al., 2011). The risk factor for infection was related to the activities of hunting and handling the carcasses, not to the consumption of meat. Virus is killed by heating for 60 min at 60°C or boiling for 5 min (CDC, online-d).

| Environment                      | Survival       | Temp. (°C) | Rel. humidity (%) | Additional conditions           | Ref.                           |
|----------------------------------|----------------|------------|-------------------|---------------------------------|--------------------------------|
| Dried on solid surface           | Up to 14 days  | 21         | 40                | -                               | (Fischer et al., 2015)         |
| In tissue culture media, dried on solid surface | Up to 50 days  | 4          | 50–55             | On glass, in darkness           | (Wittmann et al., 2007)        |
| In tissue culture media, dried on solid surface | At least 26 days | 4      | 50–55             | On plastic, in darkness         | (Wittmann et al., 2007)        |
| Water                            | Up to 6 days   | 21         | -                 | -                               | (Fischer et al., 2015)         |
| Water                            | Up to 3 days   | 27         | -                 | -                               | (Fischer et al., 2015)         |
| Domestic wastewater              | At least 8 days| -          | -                 | -                               | (Bibby et al., 2015)           |
| Air (laboratory generated aerosol) | 180 minutes    | 18–22      | 80                | -                               | (Fischer et al., 2016a)        |
| Air (laboratory generated aerosol) | 90 minutes     | 19–25      | 50–55             | -                               | (Piercy et al., 2010; Smither et al., 2011) |

Viruses with structural lipids (e.g. Ebola) survive best in dry air with a relative humidity less than 50–70% (Cox, 1995).
Direct contact with bats or bat meat have been suspected, but not confirmed, to be the source of infection see Section 3.1.1.3.

**Speed of transmission**

**Parameter 3 – Incidence between animals and, when relevant, between animals and humans**

Measures of speed of transmission between animals or between animals and humans are not known.

**Parameter 4 – Transmission rate (beta) (from \(R_0\) and infectious period) between animals and, when relevant, between animals and humans**

The transmission rate is not known. Due to the physiological and sociable similarities between great apes and humans, the transmission rate could be comparable to what has been observed in humans:

In the human outbreak in West Africa in 2013–2016, the range of estimated mean value of the basic \(R_0\) and transmission rate (for the outbreak in general and for the three main countries individually) were 1.55–2.73 and 0.20–0.45 per day, respectively (Althaus, 2014; Ahmad et al., 2016). Previous estimates of \(R_0\) in other outbreaks have ranged between 1.33 and 2.7 (Chowell and Nishiura, 2014). Great apes are highly sociable and larger outbreaks have been observed in these species (Caillaud et al., 2006; Leendertz et al., 2017).

**3.1.1.7 Article 7(a)(vii) The absence or presence and distribution of the disease in the Union, and, where the disease is not present in the Union, the risk of its introduction into the Union**

**Presence and distribution**

**Parameter 1 – Map where the disease is present in EU**

The disease is not present in the EU; limited to the tropical belt of Africa (Pigott et al., 2014; WHO, online-f).

**Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level**

Sporadic cases are reported in humans who have travelled, or who have been medically rescued, from West Africa during the 2013–2016 outbreaks (ECDC, online-e).

**Risk of introduction**

**Parameter 3 – Routes of possible introduction**

- Infected humans travelling from outbreak areas (ECDC, online-e).
- Import of contaminated bushmeat from Africa, although no cases have yet been reported out of the primary outbreaks locations due to the consumption of imported bushmeat (EFSA, 2014, 2015b). Bushmeat is meat from wild animals (endangered or not) native to Africa (Swamy and Pinedo-Vasquez, 2014; BCTF, online).
- Import of infected NHP (Rollin et al., 1999).
- Food other than bushmeat has never been identified as associated with human cases in any of the reported outbreaks. Other food products such as fruits and vegetables are unlikely routes of introduction (EFSA, 2014, 2015b).

**Parameter 4 – Number of animal moving and/or shipment size**

Illegal imports of bushmeat do exist: examples of bushmeat amounts reported in personal luggage at airports include (but not a complete list):

- France, Charles de Gaulle airport: 273 tonnes per year, mainly from Central Africa. Average consignments of bushmeat were over 20 kg (Chaber et al., 2010).
- Switzerland: 249 kg/year, mainly from West Africa. Medium weight of consignments was 4.5 kg (Falk et al., 2013).
- Austria: in 8 months bushmeat was confiscated six times (Schoder et al., 2015).

Nevertheless, the quantities mentioned above are just examples and they are not representative of the real imported amounts, which are likely to be much higher, though impossible to quantify with more accuracy. Furthermore, it should be considered that not all bushmeat is from animals susceptible to EV and contaminated by the virus.
Parameter 5 – Duration of infectious period in animal and/or commodity

Please see Section 3.1.1.5 Parameter 1. Carcasses of NHP have been documented to remain infectious up to 7 days after death (Prescott et al., 2015). Infectious period in wild bats is not known; in experimental infections, the virus could be recovered after 3 weeks (Swanepeol et al., 1996).

The virus viability is prolonged by freezing or refrigeration (Chepurnov et al., 1995; Piercy et al., 2010; Reed et al., 2011). Please, see also Section 3.1.1.5 Parameter 4. It is uncertain how long EV survives in carcasses and meat under different treatments, e.g. salting, smoking and drying which is commonly done with bushmeat (EFSA, 2014, 2015b).

Parameter 6 – List of control measures at border (testing, quarantine, etc.)

- Human travel and border health measures (ECDC, online-c);
- Personal luggage control for imported bushmeat (Commission Regulation (EC) No 206/2009);
- Control of air and sea freight;
- Illegally imported live animals: quarantine and testing and/or euthanasia;
- Public information on risk of importing bushmeat (CDC, online-g).

Parameter 7 – Presence and duration of latent infection and/or carrier status

See Section 3.1.1.5.

Parameter 8 – Risk of introduction by possible entry routes (considering parameters from 3 to 7)

It is difficult to provide a figure or a range of values of the overall risk of introduction of Ebola through the different routes because a number of factors necessary for such estimation are not known and some parameters might not be possible to estimate. The risk and uncertainties in estimating such risk of introduction through the different routes are described in general terms below.

Humans travelling from outbreak areas

Such introduction has already been proven possible several times. A medically evacuated patient entering a well prepared health care setting carries less risk of introduction to the general public than a person who is unaware that he/she is infected when leaving the outbreak area. Clearly, the larger outbreak and the more travellers from the area the higher risk of introduction.

Import of bush meat

The outcome of the assessment is the probability for at least a single case of human infected by Ebola virus in Europe due to transmission via handling and preparation (carried out by consumers or staff handling the food in kitchens immediately prior to consumption) and consumption of bush meat illegally imported from infected areas. This probability is the result of a combination of several necessary steps: (1) the bush meat has to be contaminated with Ebola virus at the point of origin; (2) the bush meat has to be (illegally) introduced into the EU; (3) the imported bush meat needs to contain viable virus when it reaches the person; (4) the person has to be exposed to the virus; and (5) the person needs to get infected following exposure.

Due to lack of data and knowledge, which results in very high uncertainty, it is not possible to estimate that risk. However, considering all the elements in these steps, and based on: (i) the limited number of outbreaks that have been reported to date in spite of the routine consumption of bush meat in that continent, (ii) the handling of bush meat in Europe not involving high risk practices such as hunting and butchering, and (iii) the assumed low overall consumption of bush meat in Europe, it can be assumed that the potential for introduction and transmission of Ebola virus via bush meat in Europe is currently low. It should be noted that the public health consequences of such an event (a single human case of Ebola virus occurring in Europe) would be very serious given the high lethality and potential for secondary transmission. In addition, it should be noted that the information considered in this opinion is largely based on historic Ebola outbreaks and not specifically the recent wide outbreak in West Africa (EFSA, 2014).

---

1 Commission Regulation (EC) No 206/2009 of 5 March 2009 on the introduction into the Community of personal consignments of products of animal origin and amending Regulation (EC) No 136/2004. OJ L 77, 24.3.2009, p. 1-19.
Import of non-human primates

Export quarantine lasting longer than the virus incubation time should in theory ensure that infected animals are not exported, unless the animals could come in contact with the virus during the stay in the export quarantine. Imported primates are not exposed directly to the general public; avoidance of infection of personnel at import quarantine stations relies on training and infection prevention. The route of infection to animal care workers has been demonstrated when Ebola Reston virus was introduced into primate quarantine station in the USA from infected primates coming from Philippines.

Food other than bush meat

In this assessment, ‘top-down’ (e.g. surveillance-based) and ‘bottom-up’ (e.g. using the standard microbial risk assessment paradigm, where the agent is followed through the food chain to produce a prediction of risk to human health relative to other agents and/or foods) approaches were combined. Using the ‘top-down’ approach, it was concluded that food other than bush meat has never been associated with human cases in any of the reported outbreaks. There is no evidence for food-borne transmission of Ebola virus to persons in the EU.

Using the ‘bottom-up’ approach, it was concluded that the necessary sequence of events in the risk pathway involves many hurdles: (1) the raw food to be exported has to be contaminated with Ebola virus at the point of origin; (2) the imported food needs to contain viable virus at sufficient load to cause human infection when it arrives in the EU; (3) the person has to be exposed to the virus through the handling and preparation (both carried out by consumers or staff handling the food in kitchens immediately prior to consumption) as well as consumption of contaminated food; and (4) the person needs to get infected following exposure. Each of these steps is necessary in order for a case of disease to occur and none have been documented to happen in practice. Due to lack of data and knowledge, which results in very high uncertainty, it is not possible to quantify the risk of food-borne transmission of Ebola virus derived from the consumption of these imported foods, or in fact whether or not this mode of transmission could occur at all.

The overall conclusions of both ‘top-down’ and ‘bottom-up’ approaches are consistent and suggest that the risk of food-borne transmission of Ebola virus via food other than bush meat imported into the EU remains a theoretical possibility only and has never been demonstrated in practice. However, the uncertainty in the combined assessment is considered high given the lack of data (EFSA, 2015b).

3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools

Diagnostic tools

Parameter 1 – Existence of diagnostic tools

- Direct detection of pathogen: polymerase chain reaction (PCR), antigen-capture enzyme-linked immunosorbent assay (ELISA), immunohistochemistry testing
- Virus isolation
- Detection of antibodies: ELISAs (IgM and IgG) (see Table 3 for test performance)

Control tools

Parameter 2 – Existence of control tools

In Europe:

- Isolation of human cases
- Contact tracing (ECDC, online-b)
- Disinfection of contaminated areas with 0.5% sodium hypochlorite as recommended by WHO (online-c).
- Incineration of imported bushmeat (CDC, online-a).
- Euthanasia of infected animals imported from Africa.

There are no licensed treatments or vaccines, however several are in human clinical trials (please see below).

In outbreak areas, safe burial practice (see Section 3.1.5.2) and avoidance of bushmeat are also recommended.
3.1.2. Article 7(b) The impact of diseases

3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture production and other parts of the economy

_The level of presence of the disease in the Union_

Parameter 1 – Number of MSs where the disease is present

- The disease is not present.

_The loss of production due to the disease_

Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation

- This is not applicable. The disease is of human health concern.

3.1.2.2. Article 7(b)(ii) The impact of the disease on human health

_Transmissibility between animals and humans_

Parameter 1 – Types of routes of transmission between animals and humans

- Contact with infected animals, carcasses, meat and body fluids from infected wildlife. So far, the virus has been isolated from carcasses of chimpanzees, gorillas and duikers however infection is likely to occur in additional species (Leroy et al., 2004a; Rouquet et al., 2005; Lahm et al., 2007; Olivero et al., 2017).
- The risk of infection from bat meat is unknown.
- The reservoir host is not determined hence additional infective sources and infection routes may exist.

Parameter 2 – Incidence of zoonotic cases

- Since 1972, 26 cases of zoonotic transmission are known to have occurred in Sub-Saharan Africa (Pigott et al., 2014; WHO, online-f). The population of Sub-Saharan Africa is 856 million people (WB, online).

_Transmissibility between humans_

Parameter 3 – Human-to-human transmission is sufficient to sustain sporadic cases or community-level outbreak

- Human-to-human transmission occurred in all but four of the known zoonotic transmissions. Before the epidemic in West Africa in 2013–2016, where the number of recorded cases was 28.600, outbreaks included up to 425 people maximum (CDC, online-f).

Parameter 4 – Sporadic, endemic, epidemic, or pandemic potential

- The disease occurs sporadically in Africa. The disease was, however, widespread in Guinea, Liberia and Sierra Leone in the 2013–2016 epidemics and the infection was imported into several countries (Mali, Senegal, Nigeria, the USA, Spain, Italy, France, Switzerland, Germany, the United Kingdom, Norway) through infected medical personnel and international travels. In Nigeria, the infection spread to 19 people (WHO, online-a). The WHO declared the Ebola epidemic to be a Public Health Emergency of International Concern in August 2014 (WHO, online-b).

_Transmission between animals and humans_

Parameter 5 – Disability-adjusted life year (DALY)

- DALY has not been calculated. Ebola virus disease first entered the Global Disease Burden list in 2015 in the group of ‘Neglected tropical diseases and Malaria’ (Global Burden of Disease 2015 Mortality and Causes of Death Collaborators, online). The years of lives lost (YLL) due to Ebola for that year was estimated to be 5.500. In total, 11,300 people were recorded to have died between December 2013–April 2016, mainly in Guinea, Sierra Leone and Liberia (CDC, online-f). The population of these three countries combined is 22.5 million people (WB, online).
Up until 2013, the overall number of recorded deaths in Sub-Saharan African countries since the disease was detected in 1976 was ca. 1,500 (CDC, online-f). The population of sub-Saharan Africa is 856 million people (WB, online).

The availability of effective prevention or medical treatment in humans

Parameter 6 – Availability of medical treatment and their effectiveness (therapeutic effect and any resistance)

No Ebola specific medical treatment is licensed. Experimental treatments are in clinical trials (see below). Treatment relies on supportive care. WHO recommends use of convalescent blood products (WHO, online-d).

Parameter 7 – Availability of vaccines and their effectiveness (reduced morbidity)

So far, no vaccine is licensed. Several vaccine candidates are in clinical trials (see below). Only one has been tested for efficacy in humans; the rVSV-EBOV vaccine candidate protected 100% of the 4,123 vaccinated in-contact people in a ring-vaccination trial during the 2013–2016 epidemic (Henao-Restrepo et al., 2017).

3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare

Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment

NHP develop haemorrhagic fever with severe clinical signs similar to humans (Kuhn, 2008; Leendertz et al., 2017). Experimental infections show that deaths in NHPs usually occur ca. 5–8 days post-infection but up to 14 days have been recorded depending on dose and species of virus (Geisbert et al., 2009; Nakayama and Saijo, 2013).

3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment

Biodiversity

Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list

CITES (online)
- Chimpanzees (Pan troglodytes); Appendix I
- Western gorilla (Gorilla gorilla); Appendix I

IUCN list (IUCN, online)
- Chimpanzees (Pan troglodytes) - Endangered
- Western gorilla (Gorilla gorilla) - Critically endangered (upgraded to critically endangered in 2007 due to EV disease)

Parameter 2 – Mortality in wild species

Ebola infection is not detected in wildlife in EU.

In Africa, large outbreaks in great apes (e.g. chimpanzees and gorillas) have led to population declines of 98% in some places and the disease is of concern for the survival of these endangered species (Leendertz et al., 2017). Observed mortality in other wildlife during human outbreaks indicate that additional species might be susceptible, e.g. mandrills (Mandrillus sp.), guenon (Cercopithecus sp.) and other NHP, as well as forest antelopes (Cephalophus sp.), bush pigs (Potamochoerus porcus), brush-tailed porcupines (Atherurus africanus) and other animals (Lahm et al., 2007; Olson et al., 2012). The infection is asymptomatic in bats (Swanepoel et al., 1996; Leroy et al., 2005).

Environment

Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife

The reservoir and/or environment maintaining the virus between recorded outbreaks is not known; central drivers involved in virus spillover are wildlife hunting, deforestation/forest fragmentation, and demographic changes of wildlife (Feldmann and Geisbert, 2011; EFSA, 2015a; Leendertz, 2016).

For stability of the virus outside hosts, please see Section 3.1.1.5 Parameter 4.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use in bioterrorism

Parameter 1 – Listed in OIE/CFSPH classification of pathogens

It is not listed (OIE, online-b).

Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group

It is listed (Berger, 2005).

Parameter 3 – Included in any other list of potential bio-agro-terrorism agents

It is listed, including:

- WHO: Category A priority agent (WHO, online-i)
- CDC: Category A Bioterrorism Agent (CDC, online-c)
- US Department of Health and Human Services: Select Agent, Tier 1 agent (HHS, online)
- National Institute of Allergy and Infectious Diseases: Priority pathogen, Category A (NIAID, online)

3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following disease prevention and control measures

3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities

Diagnostic tests that have been approved for Emergency Use Assessment and Listing procedure by WHO are shown in Table 3, with an indication of the test performance and the matrix sample to be used. The positive and negative predictive values can only be estimated using data from a cross-sectional study or other population-based study in which valid prevalence estimated can be obtained. No OIE certified diagnostic tool exists (OIE, online-a).

Table 3: Diagnostic tests for Ebola approved for Emergency Use Assessment and Listing procedure by WHO (WHO, online-g)

| Name | Type of test | Matrix | Sensitivity* (95% CI) | Specificity* (95% CI) |
|------|--------------|--------|----------------------|-----------------------|
| OraQuick® Ebola Rapid Antigen Test Kit | Immunoassay for detection of Ebola (EBOV) antigen | Cadaveric oral fluid, blood | 94.1% (83.8–98.8) | 100% (98.1–100.0) |
| SD Q Line Ebola Zaire Ag Antigen Rapid Test Kit, ReEBOV™ | Immunoassay for detection of Ebola (EBOV) antigen | Blood, plasma, serum | 84.9% (78.6–91.2) | 99.7% (99.1–100.0) |
| RealStar® Filovirus Screen RT-PCR Kit 1.0 | RT-PCR for detection of Ebola RNA (EBOV, SUDV, TAFV, BDBV) | Plasma | Performance acceptable** | – |
| Liferiver™ Ebola Virus (EBOV) Real Time RT-PCR Kit | RT-PCR for detection of Ebola RNA (EBOV, SUDV, TAFV, BDBV) | Blood, serum, plasma | Performance acceptable** | – |
| Xpert® Ebola Test | RT-PCR for detection of Ebola RNA (EBOV) | Blood | Performance acceptable*** | – |
| FilmArray Biothreat-E | RT-PCR for detection of Ebola RNA (EBOV) | Blood, urine | Performance acceptable*** | – |

EBOV: Ebola virus (Zaire); SUDV: Sudan ebolavirus; TAFV: Tai Forest ebolavirus; BDBV: Bundibugyo ebolavirus; RT-PCR: reverse transcriptase polymerase chain reaction; RNA: ribonucleic acid.

*: Sensitivity and specificity as reported by WHO public reports (WHO (online-g)).

**: Safety and performance documentation was reviewed by WHO and external experts.

***: The analytical evaluation of the tests was conducted at the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany, which is a WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research.
3.1.4.2. Article 7(d)(ii) Vaccination

No vaccine is licensed. Table 4 shows vaccine candidates that are in the most advanced stages of clinical trials, and their effectiveness tested so far. Additional candidates are under development and evaluation (Martins et al., 2016; ECDC, online-d).

Only one vaccine candidate has been tested for efficacy in humans; the rVSV-EBOV vaccine candidate protected 100% of the 4,123 vaccinated people in a ring-vaccination trial during the 2013–2016 epidemic (WHO, online-d). Duration of protection in humans not known for any candidate. Limited data on duration of protection in animal models; up to 18 months in rodent model (rVSV-ZEBOV) has been documented (Wong et al., 2015).

Table 4: Most advanced vaccine candidates against EV disease (ECDC, online-d; OIE, online-a)

| Vaccine candidate                  | Clinical trial status | Type of vaccine           | Administration route | Booster/pairing required | Effectiveness* |
|-----------------------------------|-----------------------|---------------------------|----------------------|--------------------------|----------------|
| rVSV-ZEBOV (Geisbert and Feldmann, 2011; Wong et al., 2014; Hutner et al., 2015; Agnandji et al., 2016; Marzi et al., 2016; Henao-Restrepo et al., 2017; Regules et al., 2017) | Phase III | Virus-vectored, live, replicating | IM** | No | 100%*** |
| Ad26.ZEBOV (Milligan et al., 2016) | Phase III | Virus-vectored, live, non-replicating | IM | Yes | – |
| ChAd3-Ebo (Stanley et al., 2014; De Santis et al., 2016; Ewer et al., 2016; Tapia et al., 2016) | Phase II | Virus-vectored, live, non-replicating | IM | Yes | – |
| Ad5-EBOV (Zhu et al., 2017) | Phase II | Virus-vectored, live, non-replicating | IM | Yes | – |
| MVA-BN-Filo(Ewer et al., 2016; Tapia et al., 2016) | Phase III | Virus-vectored, live, non-replicating | IM | Yes | – |

IM: Intramuscular injection.
*: One human study only. All candidates in clinical trials are protective in NHP studies.
**: Mucosal (oral or intranasal) in mouse and macaque model (Qiu et al., 2009).
***: 4123 contact people in outbreak vaccinated.

3.1.4.3. Article 7(d)(iii) Medical treatments

Availability

Parameter 1 – Types of drugs available on the market

No Ebola specific treatment is licensed. Table 5 shows experimental treatment candidates that are in the most advanced stages of clinical trials. Additional treatment candidates are under development and evaluation (ECDC, online-d; WHO, online-e). The antiviral drug favipiravir in Table 5 is licensed for human use against influenza in Japan (Furuta et al., 2013). Convalescent blood/plasma is currently the priority treatment option of WHO based on empirical evidence (WHO, online-d). The use of whole blood or plasma from survivors does not require an EU authorisation and is the responsibility of National Competent Authorities for Blood and Blood Components (ECDC, online-a).
In the provided text, there is a table that lists some of the most advanced treatment candidates for Ebola virus disease (EVD) as of the publication date of the article. The table includes details on the clinical trial status, type of treatment, administration route, and notes for each candidate. The candidates listed are CP/CBP (WHO, online-d), Favipiravir (Bai et al., 2016), Zmapp (McCarthy, 2014; Qiu et al., 2014), rVSV-EBOV (Marzi et al., 2011, 2016), and BCX4430 (Taylor et al., 2016).

The article discusses the availability and production capacity of treatments, with a focus on the limited availability of most experimental medicines. It mentions that European Blood Alliance coordinates the European stocks of convalescent blood products from survivors in the EU/EEA (EBA, online). Ca. 10,000 treatment doses of favipiravir are available (WHO, online-e), and Ca. 150 treatment doses of ZMapp are available (WHO, online-e).

Regarding effectiveness, the text notes that efficacy in humans is not determined for any treatment. Despite perceived success in the few treated on compassionate grounds, their efficacy determination remains elusive due to other interventions (WHO, online-e). Preliminary studies of favipiravir showed that this drug may increase survival rate and reduce viral load in EVD patients (Bai et al., 2016; Sissoko et al., 2016). In a retrospective clinical case series that was performed for PCR-confirmed EVD-patients in a hospital in Sierra Leone, 56.4% (22/39) of EVD-patients treated with WHO-recommended therapy plus favipiravir recovered in comparison with 35.3% (30/85) of the control EVD-patients that were treated with WHO-recommended therapy only, 52.9% of patients who received favipiravir had a >100-fold viral load reduction, compared with only 16.7% of patients in the control group (Bai et al., 2016).

The article also discusses the feasibility of treatments, specifically mentioning the way of administration. It notes that availability and production capacity, as well as the therapeutic effects on the field, are crucial factors in determining the effectiveness of treatments.

Parameter 1 – Available biosecurity measures

- Regular updates on the availability of licensed vaccines and treatments: this is likely to change rapidly (see section on vaccines and treatments) (Borio et al., 2002; Bray, 2003; Sprenger and Coulombier, 2014; Cenciarelli et al., 2015);
- Prevention of access to virus stocks: Reduce possibilities for theft of virus from laboratories or during outbreaks;
- Security at airports and other high risk places for bioterrorism attacks;
- Quarantine and biosafety routines at centres and veterinary inspection posts for non-human primates imported;
- Improved means of detection of deliberately induced disease outbreaks: recognition of an unusually large number of similar cases of severe illness over a short period of time, rapid medical recognition and rapid laboratory confirmation;
• Prevention of person-to-person transmission: isolation and health care facilities, personal protection and reliable decontamination procedures;
• Contact-tracing: rapid identification and follow-up of possibly infected people.

Effectiveness

Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction

Vaccination: Should efficient vaccines become available, they could prevent introduction of the pathogen in high-risk populations such as airport security personnel, veterinarians and animal handlers at primate importation centres, and health care employees. However, the unpredictable introduction routes of terrorist attacks make it difficult to identify all possible target populations for vaccination programmes.

Virus theft prevention: High level security and personnel control in laboratories reduce the likelihood of theft. Virus could however have been acquired by terrorist groups in the past. Acquisition of virus from infected patients or animals during outbreaks is possible.

Airport security: Unsuspicious material and possibly small volume of virus containing substance could be difficult to detect. Non-travellers can also enter airports.

Quarantine and biosafety routines at non-human primates import centres: Provided high-quality standards and routines this should be efficient to prevent virus introduction.

Other measures are not likely to be effective in preventing pathogen introduction (Borio et al., 2002; Bray, 2003; Sprenger and Coulombier, 2014; Cenciarelli et al., 2015).

Feasibility

Parameter 3 – Feasibility of biosecurity measure

• Vaccination and treatments: Should vaccines and/or treatments become available, vaccination is feasible.
• Prevention of access to virus stocks is unfeasible due to the possible existence of unregistered virus stocks and access to infectious material in outbreaks.
• Security: broadening security measures to include screening of travellers for potentially infectious biological material is theoretically feasible; however, it is unfeasible to control all airport visitors.
• Prevention of virus introduction at NHP import centres is feasible provided high-quality quarantine and biosafety standards.
• Improved means of detection of deliberately induced disease outbreaks: Feasible. It requires preparedness plans and available material.
• Prevention of person-to-person transmission: Feasible. It requires preparedness plans and available material.
• Contact tracing: Feasible. It requires preparedness and available material. A SMS system for follow up persons can be used (Tracey et al., 2015).

3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products

Availability

Parameter 1 – Available movement restriction measures

Avoid import of NHP from Africa.

Effectiveness

Parameter 2 – Effectiveness of restriction of animal movement in preventing the between-farm spread

This is not applicable. Restriction of farm animal movement in the EU is not indicated.

Feasibility

Parameter 3 – Feasibility of restriction of animal movement

Avoidance of import of non-human primates from Africa is feasible; several other supplying countries exist (Hunsmann, 2003).
3.1.4.6. Article 7(d)(vi) Killing of animals

Availability

Parameter 1 – Available methods for killing animals

Euthanasia of animals imported from Africa is available. There is no indication for killing EU animals.

Effectiveness

Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping spread of the disease

This is not applicable. There is no indication for killing EU animals.

Feasibility

Parameter 3 – Feasibility of killing animals

It is feasible to euthanise animals imported from Africa. There is no indication for killing EU animals.

3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products

Availability

Parameter 1 – Available disposal option

Incineration of confiscated bushmeat (CDC, online-a,b).

Effectiveness

Parameter 2 – Effectiveness of disposal option

Appropriately incinerated material does not pose a health risk (CDC, online-a).

Feasibility

Parameter 3 – Feasibility of disposal option

It is feasible.

3.1.5. Article 7(e) The impact of disease prevention and control measures

3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the economy as a whole

Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)

Vaccines or treatments are under development; there is no data on the cost of disease prevention and control measures.

Parameter 2 – Cost of eradication (culling, compensation)

Not applicable. Culling of farm animals in the EU is not indicated.

Parameter 3 – Cost of surveillance and monitoring

There is no data on the cost of surveillance and monitoring.

Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product

There are no costs because no restriction of EU animals or animal products is indicated.

Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to business amount of the sector)

Not applicable for farm animals. Losses and costs are associated with the prevention and effect of human disease and deaths.

3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control measures

Due to cultural issues, there were social resistance to Ebola control measures (for example, safe burial including avoiding washing and touching the dead body (WHO, online-h) in West Africa (Fairhead, online)). Such resistance is unlikely to occur in the EU.
For imported great apes, quarantine and biosafety measures are suggested. Euthanasia should be considered, if the animal is positive. Considering the severity of the symptoms it might be the most action to take in line with animal welfare, although considering these are endangered species of great apes, this may be a sensitive issue.

3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals

Parameter 1 – Welfare impact of control measures on domestic animals

No control measures in domestic animals are indicated.

Parameter 2 – Wildlife depopulation as control measure

No control measures in European wildlife are indicated.

3.1.5.4. Article 7(e)(iv) The environment and biodiversity

Environment

Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments (soil, water, feed, manure)

Sodium chlorite, recommended disinfection agent by WHO (Cook et al., 2015; WHO, online-c) is widely used in industrial cleaning and in private households. Due to its high reactivity and instability, it rapidly disappears in the environment. Sodium hydrochlorite is toxic to aquatic animals; it is however rapidly inactivated in organic matter such as in wastewater and sewage. The role of hypochlorite pollution is assumed as negligible. No secondary poisoning has been considered, hypochlorite not being transferred in the trophic chain (ECHA, online).

Biodiversity

Parameter 2 – Mortality in wild species

No control measures in European wildlife are indicated.

3.2. Assessment according to Article 5 criteria

This section presents the results of the expert judgement on the criteria of Article 5 of the AHL about Ebola virus disease (Table 6). The expert judgement was based on Individual and Collective Behavioural Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.

The minimum number of judges in the judgement was ten. The expert judgement was conducted as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).

Table 6: Outcome of the expert judgement on the Article 5 criteria for Ebola virus disease

| Criteria to be met by the disease: | Final outcome |
|-----------------------------------|--------------|
| According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria |              |
| A(i) The disease is transmissible | Y            |
| A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist in the Union | Y            |
| A(iii) The disease causes negative effects on animal health or poses a risk to public health due to its zoonotic character | Y            |
| A(iv) Diagnostic tools are available for the disease | Y            |
| A(v) Risk-mitigating measures and, where relevant, surveillance of the disease, are effective and proportionate to the risks posed by the disease in the Union | Y            |
### 3.2.1. Outcome of the assessment of Ebola virus disease according to criteria of Article 5(3) of the AHL on its eligibility to be listed

As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article 5 if it fulfils all criteria of the first set from A(i) to A(v) and at least one of the second set of criteria from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is considered fulfilled when the outcome is ‘Yes’. According to the results shown in Table 6, Ebola virus disease complies with all criteria of the first set and with two criteria of the second set, therefore it is considered eligible to be listed as laid down in Article 5 of the AHL.

### 3.3. Assessment according to Article 9 criteria

This section presents the results of the expert judgement on the criteria of Annex IV referring to categories as in Article 9 of the AHL about Ebola virus disease (Tables 7, 8, 9, 10 and 11). The expert judgement was based on ICBA approach described in detail in the opinion on the methodology. Experts have been provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 9, and the reasoning supporting their judgement. The minimum number of judges in the judgement was 10. The expert judgement was conducted as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).

### Table 7: Outcome of the expert judgement related to the criteria of section 1 of Annex IV (category A of Article 9) for Ebola virus disease

| Criteria to be met by the disease:                                                                 | Final outcome |
|--------------------------------------------------------------------------------------------------|---------------|
| The disease needs to fullfi all of the following criteria                                        |               |
| 1                                                                                               |               |
| The disease is not present in the territory of the Union OR present only in exceptional cases   | Y             |
| (irregular introductions) OR present in only in a very limited part of the territory of the Union|               |
| 2.1 The disease is highly transmissible                                                         | NC            |
| 2.2 There be possibilities of airborne or waterborne or vector-borne spread                      | NC            |
| 2.3 The disease affects multiple species of kept and wild animals OR single species of kept      | NC            |
| animals of economic importance                                                                  |               |
| 2.4 The disease may result in high morbidity and significant mortality rates                    | Y             |
**At least one criterion to be met by the disease:**

In addition to the criteria set out above at point 1–2.4, the disease needs to fulfil at least one of the following criteria:

| Criteria | Description |
|----------|-------------|
| 3        | The disease has a zoonotic potential with significant consequences on public health, including epidemic or pandemic potential OR possible significant threats to food safety | NC |
| 4        | The disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals | N |
| 5(a)     | The disease has a significant impact on society, with in particular an impact on labour markets | NC |
| 5(b)     | The disease has a significant impact on animal welfare, by causing suffering of large numbers of animals | N |
| 5(c)     | The disease has a significant impact on the environment, due to the direct impact of the disease OR due to the measures taken to control it | N |
| 5(d)     | The disease has a significant impact on a long-term effect on biodiversity or the protection of endangered species or breeds, including the possible disappearance or long-term damage to those species or breeds | N |

Colour code: green = consensus (Yes/No), yellow = no consensus (NC).

**Table 8:** Outcome of the expert judgement related to the criteria of section 2 of Annex IV (category B of Article 9) for Ebola virus disease

| Criteria to be met by the disease: | Final outcome |
|-----------------------------------|---------------|
| The disease needs to fulfil all of the following criteria |               |
| 1                                 | N             |
| 2.1                               | NC            |
| 2.2                               | NC            |
| 2.3                               | Y             |
| 2.4                               | N             |

**At least one criterion to be met by the disease:**

In addition to the criteria set out above at point 1–2.4, the disease needs to fulfil at least one of the following criteria:

| Criteria | Description |
|----------|-------------|
| 3        | The disease has a zoonotic potential with significant consequences on public health, including epidemic or pandemic potential OR possible significant threats to food safety | Y |
| 4        | The disease has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals | N |
| 5(a)     | The disease has a significant impact on society, with in particular an impact on labour markets | NC |
| 5(b)     | The disease has a significant impact on animal welfare, by causing suffering of large numbers of animals | N |
| 5(c)     | The disease has a significant impact on the environment, due to the direct impact of the disease OR due to the measures taken to control it | N |
| 5(d)     | The disease has a significant impact on a long-term effect on biodiversity or the protection of endangered species or breeds, including the possible disappearance or long-term damage to those species or breeds | N |

Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
3.3.1. Non-consensus questions

This section displays the assessment related to each criterion of Annex IV referring to the categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 13, 14, 15, 16 and 17). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting views for each answer.

### Table 9: Outcome of the expert judgement related to the criteria of section 3 of Annex IV (category C of Article 9) for Ebola virus disease

| Criteria to be met by the disease: | Final outcome |
|-----------------------------------|---------------|
| The disease needs to fulfil all of the following criteria | N |
| 1. The disease is present in the whole OR part of the Union territory with an endemic character | N |
| 2.1 The disease is moderately to highly transmissible | NC |
| 2.2 The disease is transmitted mainly by direct or indirect transmission | Y |
| 2.3 The disease affects single or multiple species | Y |
| 2.4 The disease usually does not result in high morbidity and has negligible or no mortality AND often the most observed effect of the disease is production loss | N |

**At least one criterion to be met by the disease:**
In addition to the criteria set out above at point 1–2.4, the disease needs to fulfil at least one of the following criteria

| Criteria | Final outcome |
|----------|---------------|
| 3. The disease has a zoonotic potential with significant consequences on public health, or possible significant threats to food safety | Y |
| 4. The disease has a significant impact on the economy of parts of the Union, mainly related to its direct impact on certain types of animal production systems | N |
| 5(a) The disease has a significant impact on society, with in particular an impact on labour markets | NC |
| 5(b) The disease has a significant impact on animal welfare, by causing suffering of large numbers of animals | N |
| 5(c) The disease has a significant impact on the environment, due to the direct impact of the disease OR due to the measures taken to control it | N |
| 5(d) The disease has a significant impact on a long-term effect on biodiversity or the protection of endangered species or breeds, including the possible disappearance or long-term damage to those species or breeds | N |

Colour code: green = consensus (Yes/No), yellow = no consensus (NC).

### Table 10: Outcome of the expert judgement related to the criteria of section 4 of Annex IV (category D of Article 9) for Ebola virus disease

| Criteria to be met by the disease: | Final outcome |
|-----------------------------------|---------------|
| The disease needs to fulfil all of the following criteria | Y |
| The disease fulfils criteria of section 1, 2, 3 or 5 of Annex IV of AHL | Y |

Colour code: green = consensus (Yes/No).

### Table 11: Outcome of the expert judgement related to the criteria of section 5 of Annex IV (category E of Article 9) for Ebola virus disease

| Diseases in category | Final outcome |
|----------------------|---------------|
| E need to fulfil criteria of Sections 1, 2 or 3 of Annex IV of AHL and/or the following: | Y |
| Surveillance of the disease is necessary for reasons relating to animal health, animal welfare, human health, the economy, society or the environment (If a disease fulfils the criteria as in Article 5, thus being eligible to be listed, consequently category E would apply.) | Y |

Colour code: green = consensus (Yes/No).

3.3.1. Non-consensus questions

This section displays the assessment related to each criterion of Annex IV referring to the categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 13, 14, 15, 16 and 17). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting views for each answer.
Reasoning supporting the judgement

Supporting Yes for 2.1 (cat.A):
- The disease is highly transmissible in humans and thus potentially also in great apes.

Supporting Yes for 2.1 (cat.B,C):
- Based on $R_0$ values reported in humans, the transmission is not high.
- Not all Ebola strains are highly transmissible.

Supporting No:
- Direct contact with body fluid is the main route of spread.
- According to ECDC, Ebola virus disease is not an airborne disease.
- Aerosol transmission has been demonstrated only in experimental conditions, while the major route is direct transmission.
- Survival in water does not necessarily imply waterborne transmission of infection.
- Flaviviruses have very little or no capacity to be transmitted by the airborne route.

Supporting na:
- Transmission chains and routes are not known for most animals.

Table 12: Outcome of the expert judgement related to criterion 2.1 of Article 9

| Question | Final outcome | Response |
|----------|---------------|----------|
| 2.1 (cat.A) | The disease is highly transmissible | NC | 70 30 0 |
| 2.1 (cat.B,C) | The disease is moderately to highly transmissible | NC | 30 70 0 |

NC: no consensus; number of judges: 10.

Reasoning supporting the judgement

Supporting Yes:
- Experimental aerosol infection documented in NHP, pigs, mice, and guinea pigs.
- EV survival in water at 21 or 27°C can be for days, so the disease might be potentially waterborne.

Supporting No:
- Aerosol transmission has been demonstrated only in experimental conditions, while the major route is direct transmission.
- Survival in water does not necessarily imply waterborne transmission of infection.
- Flaviviruses have very little or no capacity to be transmitted by the airborne route.

Supporting na:
- Transmission chains and routes are not known for most animals.

Table 13: Outcome of the expert judgement related to criterion 2.2 of Article 9

| Question | Final outcome | Response |
|----------|---------------|----------|
| 2.2 (cat.A,B) | There be possibilities of airborne or waterborne or vector-borne spread | NC | 30 20 50 |

NC: no consensus; number of judges: 10.

Reasoning supporting the judgement

Supporting Yes:
- Experimental aerosol infection documented in NHP, pigs, mice, and guinea pigs.
- EV survival in water at 21 or 27°C can be for days, so the disease might be potentially waterborne.

Supporting No:
- Aerosol transmission has been demonstrated only in experimental conditions, while the major route is direct transmission.
- Survival in water does not necessarily imply waterborne transmission of infection.
- Flaviviruses have very little or no capacity to be transmitted by the airborne route.

Supporting na:
- Transmission chains and routes are not known for most animals.

Table 14: Outcome of the expert judgement related to criterion 2.3 of Article 9

| Question | Final outcome | Response |
|----------|---------------|----------|
| 2.3 (cat.A) | The disease affects multiple species of kept and wild animals OR single species of kept animals of economic importance | NC | 80 20 0 |

NC: no consensus; number of judges: 10.

Reasoning supporting the judgement

Supporting Yes:
- Animals (NHPs) can be experimentally affected.
- Naturally susceptible species in the EU are present in zoos.
- Pigs can be experimentally infected and they may develop a respiratory form of the disease.
Supporting No:
- No susceptible domestic or free-range wild animals are present in the EU.

Table 15: Outcome of the expert judgement related to criterion 3 of Article 9

| Question | Final outcome | Response |
|----------|---------------|----------|
| 3 (cat. A) | The disease has a zoonotic potential with significant consequences on public health, including epidemic or pandemic potential OR possible significant threats to food safety | NC | 70 | 30 | 0 |

NC: no consensus; number of judges: 10.

Reasoning supporting the judgement

Supporting Yes:
- There may be pandemic potential in humans. It is not certain that biosecurity measures are able to prevent a pandemic spread, e.g. if a large-scale epidemic is present among humans in a country with a lot of exchanges with the rest of the world (aircraft travelling).
- There have been cases of widespread disease deeming the Ebola epidemic a Public Health Emergency of International Concern in August 2014 (see Section 3.1.2.2).

Supporting No:
- The EV disease leads to potential significant consequences to public health with epidemic potential although without pandemic potential. According to the definition of a pandemic by ECDC, ‘an epidemic occurring worldwide, or over a very wide area, crossing international boundaries and usually affecting a large number of people’, the introduction of EV into EU would not lead to such a big scale spread, but it would be rather contained due to implementation of control and hygienic measures.

Table 16: Outcome of the expert judgement related to criterion 5(a) of Article 9

| Question | Final outcome | Response |
|----------|---------------|----------|
| 5(a) | The disease has a significant impact on society, with in particular an impact on labour markets | NC | 30 | 70 | 0 |

NC: no consensus; number of judges: 10.

Reasoning supporting the judgement

Supporting Yes:
- In the 2013–2016 epidemic in Africa, the impact on labour markets was catastrophic.
- EV disease could have an impact on labour markets in the EU, but not related specifically to agricultural production.
- The impact on society and labour markets would depend on the extent of epidemics in humans. It may have potentially an impact on domestic species in the EU, but not currently.

Supporting No:
- No domestic species were affected during the outbreaks in Africa, further the possible role of pigs (which are experimentally susceptible to Ebola) remains mostly unclear. Therefore, the impact on labour market is not significant due to its effect purely on domestic species.
3.3.2. Outcome of the assessment of criteria in Annex IV for Ebola virus disease for the purpose of categorisation as in Article 9 of the AHL

As from the legal text of the AHL, a disease is considered fitting in a certain category (A, B, C, D or E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union intervention as laid down in Article 5(3) and fulfils all criteria of the first set from 1 to 2.4 and at least one of the second set of criteria from 3 to 5(d) as shown in Tables 7–11. According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is considered fulfilled when the outcome is 'Yes'.

A description of the outcome of the assessment of criteria in Annex IV for Ebola for the purpose of categorisation as in Article 9 of the AHL is presented in Table 17.

Table 17: Outcome of the assessment of criteria in Annex IV for Ebola virus disease for the purpose of categorisation as in Article 9 of the AHL

| Category | Article 9 criteria | 1° set of criteria | 2° set of criteria |
|----------|--------------------|--------------------|--------------------|
|          | 1                  | 2.1                | 2.2                | 2.3                | 2.4                | 3                 | 4                 | 5a                | 5b                | 5c                | 5d                |
| Geographical distribution | Y | NC | NC | NC | Y | NC | N | NC | N | N | N |
| Transmissibility | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Routes of transmission | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Multiple species | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Morbidity and mortality | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Zoonotic potential | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Impact on economy | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Impact on society | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Impact on animal welfare | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Impact on environment | Y | N | NC | NC | Y | N | NC | N | N | N | N |
| Impact on biodiversity | Y | N | NC | NC | Y | N | NC | N | N | N | N |

According to the assessment here performed, Ebola complies with the following criteria of the sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules referred to in points (a) to (e) of Article 9(1):

1) To be assigned to category A, a disease needs to comply with all criteria of the first set (1, 2.1–2.4) and according to the assessment Ebola complies with criteria 1 and 2.4 and the assessment was inconclusive on compliance with criteria 2.1, 2.2 and 2.3. To be eligible for category A, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5a–d) and Ebola disease does not comply with criteria 4, 5b, 5c and 5d and the assessment is inconclusive on compliance with criteria 3 and 5a.

2) To be assigned to category B, a disease needs to comply with all criteria of the first set (1, 2.1–2.4) and according to the assessment Ebola disease complies with criterion 2.3, does not comply with criteria 1 and 2.4 and the assessment is inconclusive on compliance with criterion 2.1 and 2.2. To be eligible for category B, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5a–d) and Ebola disease complies with criterion 3 and does not comply with criteria 4, 5b, 5c and 5d, and the assessment is inconclusive on compliance with criterion 5a.

3) To be assigned to category C, a disease needs to comply with all criteria of the first set (1, 2.1–2.4) and according to the assessment Ebola disease complies with criteria 2.2 and 2.3, does not comply with criteria 1 and 2.4 and the assessment is inconclusive on compliance with criterion 2.1. To be eligible for category B, a disease needs to comply additionally with one of the criteria of the second set (3, 4, 5a–d) and Ebola complies with criterion 3, does not comply with criteria 4, 5b, 5c and 5d the assessment is inconclusive on compliance with criterion 5a.

4) To be assigned to category D, a disease needs to comply with criteria of section 1, 2, 3 or 5 of Annex IV of the AHL and with the specific criterion D of section 4, which Ebola disease complies with.

5) To be assigned to category E, a disease needs to comply with criteria of section 1, 2 or 3 of Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment. The latter is applicable if a disease fulfils the criteria as in Article 5, which Ebola disease complies with.

### 3.4. Assessment of Article 8

This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about Ebola virus disease. The Article 8(3) criteria are about animal species to be listed, as it reads below:

'3. Animal species or groups of animal species shall be added to this list if they are affected or if they pose a risk for the spread of a specific listed disease because:

a) they are susceptible for a specific listed disease or scientific evidence indicates that such susceptibility is likely; or

b) they are vector species or reservoirs for that disease, or scientific evidence indicates that such role is likely'.

For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of transmission, which cover also possible role of biological or mechanical vectors. According to the mapping, as presented in Table 5, Section 3.2 of the scientific opinion on the ad hoc methodology (EFSA AHAW Panel, 2017), the main animal species to be listed for Ebola virus disease according to the criteria of Article 8(3) of the AHL are as displayed in Table 18.

#### Table 18: Main animal species to be listed for Ebola virus disease according to criteria of Article 8

(source: data reported in Section 3.1.1.1)

| Class | Order | Family | Genus/Species |
|-------|-------|--------|---------------|
| Susceptible* | Mammalia | Primates | Hominidae | Gorilla gorilla | Pan troglodytes |
| | | | Cercopithecidae | Macaca mulatta | Macaca fascicularis | Papio spp. | Chlorocebus pygerythrus | Cercopithecus aethiops |
| | | | Callitrichidae | Callithrix jacchus |
| | Chiroptera | Pteropodidae | Epomops franqueti | Hypsignathus monstrosus | Myonycteris torquata | Rousettus aegyptiacus | Epomophorus wahlbergi |
| | | | Molossidae | Mops condylurus | Tadarida pumila | Chaerephon pumilus |
| Rodentia | Muridae | | Mus setulosus | Praomys spp | Mus spp.* |
| | | | Cricetidae | Mesocricetus auratus* |
| | | | Caviidae | Cavia porcellus* |
| Eulipotyphla | Soricidae | | Sylvisorex allula |
| Carnivora | Mustelidae | | Mustela putorius furo |
| | Bovidae | | Cephalophus dorsalis |
| | Suidae | | Sus scrofa |

---

2 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected for shorter time than in biological vectors.
4. Conclusions

TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;

- According to the assessment here performed, Ebola complies with all criteria of the first set and with two criteria of the second set and therefore can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.

TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of categorisation of diseases in accordance with Article 9 of the AHL;

- According to the assessment here performed, Ebola meets the criteria as in sections 4 and 5 of Annex IV of the AHL, for the application of the disease prevention and control rules referred to in points (d) and (e) of Article 9(1) of the AHL.

TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of animal species that should be considered candidates for listing in accordance with Article 8 of the AHL;

- According to the assessment here performed, the animal species that can be considered to be listed for Ebola according to Article 8(3) of the AHL are some species of non-human primates, pigs and rodents as susceptible species and some species of fruit bats as reservoir, as reported in Table 18 in Section 3.4 of the present document.

References

Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Alfeld M, Auderset F, Bache EB, Biedenkopf N, Borrer, S, Brosnaham JS, Burrow R, Combescure C, Desmeules J, Eckmann M, Fehling, SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Leil B, Lemaitre B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmuller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kienny MP, Bejon P, Kremsner PG, Addo MM and Siegrist CA, 2016. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. The New England Journal of Medicine, 374, 1647–1660.

Ahmad MD, Usman M, Khan A and Imran M, 2016. Optimal control analysis of Ebola disease with control strategies of quarantine and vaccination. Infectious Diseases of Poverty, 5, 72.

Allela L, Boury O, Pouillot R, Delicat A, Yaba P, Kumulungui B, Rouquet P, Gonzalez JP and Leroy EM, 2005. Ebola virus antibody prevalence in dogs and human risk. Emerging Infectious Diseases, 11, 385–390.

Althaus CL, 2014. Estimating the Reproduction Number of Ebola Virus (EBOV) during the 2014 outbreak in West Africa. PLOS Currents, 6, Edition 1. https://doi.org/10.1371/currents.outbreaks.91af850f279e7f29e705609525bb288

Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM, Kanu A, Liu WW, Wang YP, Dafae F, Yan T, Hu Y, Deng YQ, Lu HJ, Yang F, Zhang XG, Sun Y, Cao YX, Su HX, Sun Y, Liu WS, Wang CY, Qian J, Liu L, Wang H, Tong YG, Liu ZY, Chen YS, Wang HQ, Kargbo B, Gao GF and Jiang JF, 2016. Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-sierra leone, 2014. Clinical Infectious Diseases, 63, 1288–1294.

Banadyga L, Dolan MA and Ebihara H, 2016. Rodent-adapted filoviruses and the molecular basis of pathogenesis. Journal of Molecular Biology, 428, 3449–3466.

Baron RC, McCormick JB and Zubeir OA, 1983. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bulletin of the World Health Organization, 61, 997–1003.

BCTF (Bushmeat Crisis Task Force), online. Species Affected by the Bushmeat Trade in Africa. Available online: http://www.bushmeat.org/sites/default/files/Species/Affected.pdf. [Accessed: 18 October 2016]
Becquart P, Wauquier N, Mahlakov T, Nkoghe D, Padilla C, Souris M, Ollomo B, Gonzalez JP, De Lamballerie X, Kazanji M and Leroy EM, 2010. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS ONE, 5, e9126.

Berger SA, 2005. Hemorrhagic fever viruses. Available online; https://doi.org/10.1002/0471686786.ebd0059

Bibby K, Fischer RJ, Casson LW, Stachler E, Haas CN and Munster VJ, 2015. Persistence of Ebola virus in sterilized wastewater. Environmental Science & Technology Letters, 2, 245–249.

Borio L, Ingleby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O’Toole T, Ascher MS, Bartlett J, Breman JG, Enzen EM Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P and Tonat K, 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA, 287, 2391–2405.

Bowen ET, Platt GS, Simpson DI, McArdell LB and Raymond RT, 1978. Ebola haemorrhagic fever: experimental infection of monkeys. Transactions of the Royal Society of Tropical Medicine and Hygiene, 72, 188–191.

Bray M, 2003. Defense against filoviruses used as biological weapons. Antiviral Research, 57, 53–60.

Caillaud D, Levrero F, Cristescu R, Gatti S, Dewas M, Douadi M, Gautier-Hion A, Raymond M and Menard N, 2006. Gorilla susceptibility to Ebola virus: the cost of sociality. Current Biology, 16, 489–491.

CDC (Centers for Disease Control and Prevention), online-a. Guidance for Safe Handling of Human Remains of Ebola Patients in U.S. Hospitals and Mortuaries. Available online: http://www.cdc.gov/vhf/ebola/hospitals/handling-human-remains.html [Accessed: 12 October 2016]

CDC (Centers for Disease Control and Prevention), online-b. Ebola-Associated Waste Management. Available online: http://www.cdc.gov/vhf/ebola/hospitals/handling-human-remains.html [Accessed: 12 October 2016]

CDC (Centers for Disease Control and Prevention), online-c. Bioterrorism Agents. Available online: https://emergency.cdc.gov/agent/agentlist.asp [Accessed: 18 October 2016]

CDC (Centers for Disease Control and Prevention), online-d. Information on the Survivability of the Ebola Virus in Medical Waste. Available online: http://www.cdc.gov/vhf/ebola/hospitals/cleaning/ebola-virus-survivability.html [Accessed: 18 October 2016]

CDC (Centers for Disease Control and Prevention), online-e. About Ebola Hemorrhagic Fever. Available online: http://www.cdc.gov/vhf/ebola/about.html [Accessed: 12 October 2016]

CDC (Centers for Disease Control and Prevention), online-f. Outbreaks Chronology: Ebola Virus Disease. Available online: http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html [Accessed: 8 October 2016]

CDC (Centers for Disease Control and Prevention), online-g. Facts about Bushmeat and Ebola. Available online: http://www.cdc.gov/vhf/ebola/about.html [Accessed: 12 October 2016]

CDC (Centers for Disease Control and Prevention), online-h. Ebola-Associated Waste Management. Available online: http://www.cdc.gov/vhf/ebola/hospitals/cleaning/ebola-virus-survivability.html [Accessed: 18 October 2016]

Chaber A-L, Allebone-Webb S, Lignereux Y, Cunningham AA and Marcus Rowcliffe J, 2010. The scale of illegal meat exportation from Africa to Europe via Paris. Conservation Letters, 3, 317–321.

Chepurnov AA, Chev IuP, PTankov OV and Efimova IV, 1995. The effect of some physical and chemical factors on inactivation of the Ebola virus. Voprosy Virusologii, 40, 74–76.

Cheresiz SV, Semenova EA and Chepurnov AA, 2016. Adapted lethality: what we can learn from Guinea Pig-Adapted Ebola virus infection model. Advances in Virology, 2016, 8059607.

Chowell G and Nishiura H, 2014. Transmission dynamics and control of Ebola virus disease (EVD): a review. BMC Medicine, 12, 196.

CITES (Convention on International Trade in Endangered Species of Wild Fauna and Flora), online. CITES. Available online: https://cites.org/eng/ [Accessed: 12 October 2016]

Cook BW, Cutts TA, Nikiforuk AM, Poliquin PG, Court DA, Strong JE and Theriault SS, 2015. Evaluating environmental persistence and disinfection of the Ebola virus Makona variant. Viruses, 7, 1975–1986.

Cox C, 1995. Bioaerosol Handbook. FL, USA, Boca Raton. pp. 77–99.

Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA and Geisbert TW, 2016. The Domestic ferret (Mustela putorius furo) as a lethal infection model for 3 Species of ebolavirus. The Journal of Infectious Diseases, 214, 565–569.

Davis KJ, Anderson AO, Geisbert TW, Steele KE, Geisbert JB, Vogel P, Connolly BM, Huggins JW, Jahrling PB and Jaax NK, 1997. Pathology of experimental Ebola virus infection in african green monkeys. involvement of fibroblastic reticular cells. Archives of Pathology & Laboratory Medicine, 121, 805–819.

De Santis O, Audran R, Pothin E, Warpelin-Decrausz L, Vallotlon L, Wuerzner G, Crochet C, Estoppey D, Steiner-Monard V, Lanchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Plouquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F and Genton B, 2016. Safety and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. The Lancet. Infectious Diseases, 16, 311–320.

Dedkova L, 1993. Antibodies of hyperimmune sera of animals. II. Subclasses of IgG from normal and hyperimmune sera of goat. Sibirskij biologicheskij zhurnal (Russian Federation), 6, 8–13.

EBA (European Blood Alliance), online. European Blood Alliance. Available online: http://www.sweba.se/sites/default/files/EBANewsletter2015_1.pdf [Accessed: 14 October 2016]

EBA (European Blood Alliance), online. European Blood Alliance. Available online: http://www.sweba.se/sites/default/files/EBANewsletter2015_1.pdf [Accessed: 14 October 2016]

Jaax NK, 1997. Pathology of experimental Ebola virus infection in african green monkeys. involvement of broblastic reticular cells. Archives of Pathology & Laboratory Medicine, 121, 805–819.

Kazanji M and Leroy EM, 2010. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS ONE, 5, e9126.

Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P and Tonat K, 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA, 287, 2391–2405.

Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P and Tonat K, 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA, 287, 2391–2405.

Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P and Tonat K, 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA, 287, 2391–2405.
Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R, Rosenke R, Long D, Haddock E, Fischer E, Kawaoka Y and Feldmann H, 2013. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. The Journal of Infectious Diseases, 207, 306–318.

ECDC (European Centre for Disease Control and Prevention), online-a. Factsheet for health professionals. Available online: http://ecdc.europa.eu/en/healthtopics/ebola_marburg_fever/factsheet-for-health-professionals/pages/factsheet_health_professionals.aspx [Accessed: 10 October 2016]

ECDC (European Centre for Disease Control and Prevention), online-b. Public health management of persons having had contact with Ebola virus disease cases in the EU. Available online:cdc.europa.eu/en/publications/publications/ebola-public-health-contact-management-update-10-november.pdf [Accessed: 18 October 2016]

ECDC (European Centre for Disease Control and Prevention), online-c. Entry and exit screening measures. Available online: http://ecdc.europa.eu/en/publications/Publications/Ebola-outbreak-technicalreport-exit-entry-screening-13oct2014.pdf [Accessed: 18 October 2016]

ECDC (European Centre for Disease Control and Prevention), online-d. Treatment and vaccine development. Available online: http://ecdc.europa.eu/en/healthtopics/ebola_marburg_fever/Pages/treatment-vaccines.aspx [Accessed: 11 October 2016]

ECDC (European Centre for Disease Prevention and Control), online-e. Epidemiological update: outbreak of Ebola virus disease in West Africa. Available online: http://ecdc.europa.eu/en/press/news_/layouts/forms/News_DispForm.aspx?List=8db7286c-fe2d-476c-9133-18f4cb1b568b&ID=1113 [Accessed: 11 October 2016]

ECHA (European Chemicals Agency). Available online: https://echa.europa.eu/documents/10162/330f3ee6d-3220-4db1-4add-3df9bc3e2e5e [Accessed: 12 October 2016]

EFSACostBenefitAnalysis (European Food Safety Authority), 2014. An update on the risk of transmission of Ebola virus (EBOV) via the food chain. EFSA Journal 2014;12(11):3884, 25 pp. https://doi.org/10.2903/j.efsa.2014.3884

EFSACostBenefitAnalysis (European Food Safety Authority), 2015a. Scientific report on drivers for occasional spillover event of Ebola virus. EFSA Journal 2015;13(6):4161, 46 pp. doi:10.2903/j.efsa.2015.4161

EFSACostBenefitAnalysis (European Food Safety Authority), 2015b. An update on the risk of transmission of Ebola virus (EBOV) via the food chain – Part 2. EFSA Journal 2015;13(3):4042, 17 pp. https://doi.org/10.2903/j.efsa.2015.4042

EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare), More S, Betner A, Butterworth A, Calistrri P, Depner K, Edwards S, Garin-Bastuji B, Good M, Gortazar Schmidt C, Michel V, Miranda MA, Nielsen SS, Raj M, Sihvonen L, Spoolder H, Stegeman JA, Thulke HH, Velarde A, Willeberg P, Winckler C, Baldinelli F, Brogila A, Candiani D, Gervelmeyer A, Zancanaro G, Kohnle L, Morgado J and Bicout D, 2017. Scientific opinion on an ad hoc method for the assessment on listing and categorisation of animal species within the scope of the Animal Health Law. EFSA Journal 2017;15(5):4783, 42 pp. https://doi.org/10.2903/j.efsa.2017.4783

Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krahnig V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbe G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powell J, Berrie E, Pedder R, Roman F, De Ryck I, Dianati M, Holmberg S, Conner M, Diamantoglou E, Spedicato A, Locatelli L, Cao Z, Zardetto Simonetti G, Humpage AR, Lourenco C, de la Torre A, van der Poel H, Picheral M, Al Toyota K, Döpp S, de Lichte H, de Haan C, de Wit T, de Wit E, de Graaf C, de Jong M, van der Klis M, van der Klis S, van den Broek E, van der Linden J, van der Linden M, van der Linden R, van der Linden B, van der Linde L, van der Linden A, van der Linden N, van der Linden O, van der Linden V, van der Linden J, van der Linden H, van der Linden F, van der Linden E, van der Linden D, van der Linden C, van der Linden B, van der Linden A, van der Linden 2017. Scientific opinion on the evaluation of the potential hazard and risk of transmission of Zaire ebolavirus from the 1976 and 2013 outbreaks. The Journal of Infectious Diseases, 214, 290–293.

Feldmann H and Geissb C, 2011. Ebola haemorrhagic fever. Lancet, 377, 849-862.

Fischer R, Judson S, Miazgowicz K, Bushmaker T, Prescott J and Munster VJ, 2015. Ebola virus stability on surfaces and in fluids in simulated outbreak environments. Emerging Infectious Diseases, 21, 1243–1246.

Fischer RJ, Bushmaker T, Judson S and Munster VJ, 2016a. Comparison of the aerosol stability of 2 Strains of Zaire ebolavirus From the 1976 and 2013 Outbreaks. The Journal of Infectious Diseases, 214, 290–293.

Fischer RJ, Judson S, Miazgowicz K, Bushmaker T and Munster VJ, 2016b. Ebola virus persistence in semen. Emerg Infectious Diseases, 22, 289–291.

Fisher-Hoch SP, Perez-Oronoz GI, Jackson EL, Herrmann LM and Brown BG, 1992. Filovirus clearance in non-human primates. Lancet, 340, 451–453.

Fompey P, Boesch C, Wyers M, Steiner C, Donati F, Dind F, Walker F and Le Guenno, B, 1999. Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d’Ivoire. The Journal of Infectious Diseases, 179, 120–126.

Furuta Y, Gowenb Brian B, Takahashia K, Shirakic K, Smeed Donald F and Barnardb DL, 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research, 100, 446–454.

Geissb TW and Feldmann H, 2011. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. The Journal of Infectious Diseases, 204, 1075–1081.
Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A and Feldmann H, 2009. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. Journal of Virology, 83, 7296–7304.

Geisbert TW, Strong JE and Feldmann H, 2015. Considerations in the use of nonhuman primate models of Ebola Virus and marburg virus infection. The Journal of Infectious Diseases, 212, 91–97.

Georges AJ, Leroy EM, Renault AA, Benissan CT, Nabias RJ, Ngoc MT, Obiang PI, Lepage JP, Bertherat EJ, Benoni DD, Wickings EJ, Amblard JP, Lansoud-Soukate JM, Milleli RJ, Baize S and Georges-Courbot MC, 1999. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. The Journal of Infectious Diseases, 179, 65–75.

Georges-Courbot MC, Lu CY, Lansoud-Soukate J, Leroy E and Baize S, 1997a. Isolation and partial molecular characterisation of a strain of Ebola virus during a recent epidemic of viral haemorrhagic fever in Gabon. Lancet, 349, 181.

Georges-Courbot MC, Sanchez A, Lu CY, Baize S, Leroy E, Lansout-Soukate J, Tevi-Benissan C, Georges AJ, Trappier SG, Zaki SR, Swanepool R, Leman PA, Rollin PE, Peters CJ, Nichol ST and Ksiazek TG, 1997b. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerging Infectious Diseases, 3, 59–62.

Global Burden of Disease 2015 Mortality and Causes of Death Collaborators, online. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Available online: http://thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)31012-1.pdf [Accessed: 14 October 2016]

Heymann DL, Weisfeld JS, Webb PA, Johnson KM, Cairns T and Berquist H, 1980. Ebola hemorrhagic fever: today, 1977-1978. The Journal of Infectious Diseases, 142, 372–376.

HHS (United States Department of Health and Human Services), online. Federal Select Agent Program - Select Agents and Toxins List. Available online: http://www.selectagents.gov/SelectAgentsandToxinsList.html [Accessed: 11 October 2016]

Hunsmann G, 2003. Nonhuman Primates in Preclinical Research: The EU Situation. National Academies Press (US).

Hyman DT, Emmerich P, Yu M, Wang LF, Suu-Ire R, Fooks AR, Cunningham AA and Wood JL, 2010. Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS ONE, 5, e11978.

Hunsmann G, 2003. Nonhuman Primates in Preclinical Research: The EU Situation. National Academies Press (US).

IUCN (International Union for the Conservation of Nature), online. IUCN. Available online: https://www.iucn.org/ [Accessed: 11 October 2016]

Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, Nagley D, Johnson E, Jaax G and Peters C, 1995. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet, 346, 1669–1671.

Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, Nagley D, Johnson E, Jaax G and Peters C, 1995. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet, 346, 1669–1671.

Johnson E, Jaax N, White J and Jahrling P, 1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. International Journal of Experimental Pathology, 76, 227–236.

Jones ME, Schuh AJ, Amman BR, Sealy TK, Zaki SR, Nichol ST and Towner JS, 2015. Experimental inoculation of Egyptian rousette bats (Rousettus aegyptiacus) with Viruses of the ebolavirus and marburgvirus genera. Viruses, 7, 3420–3442.

Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, Smith G, Tierney K, Patel A and Weingartl HM, 2011. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. The Journal of Infectious Diseases, 204, 200-208.

Krasnianski BP, Mikhailov VV, Borisevich IV, Gradoboev VN, Eversev AA and Pshenichnov VA, 1995. Preparation of hyperimmune horse serum against Ebola virus. Voprosy Virusologii, 40, 138–140.
Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA and Netesov SV, 1999. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. The Journal of Infectious Diseases, 179, 218–223.

Kuhn JH, 2008. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Archives of Virology. Supplementum, 20, 13–360.

Lahm SA, Kombila M, Swanepoel R and Barnes RF, 2007. Morbidity and mortality of wild animals in relation to outbreaks of Ebola haemorrhagic fever in Gabon, 1994–2003. Transactions of the Royal Society of Tropical Medicine and Hygiene, 101, 64–78.

Leendertz S, 2016. Testing new hypotheses regarding ebolavirus reservoirs. Viruses, 8, 30.

Leendertz SA, Vogten SP, Rouquet P, Souquiere S, Kilbourne A, Froment JM, Bermejo M, Smit S, Karesh W, Swanepoel R, Zaki SR and Rollin PE, 2004a. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science, 303, 387–390.

Leeroy EM, Teifler P, Kulumugui B, Yaba P, Rouquet P, Roques P, Gonzalez JP, Ksiazek TG, Rollin PE and Netten E, 2004b. A serological survey of Ebola virus infection in central African nonhuman primates. The Journal of Infectious Diseases, 190, 1895–1899.

Leeroy EM, Kulumugui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delacat A, Paweska JT, Gonzalez JP and Swanepoel R, 2005. Fruit bats as reservoirs of Ebola virus. Nature, 438, 575–576.

Leeroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ and Formenty P, 2009. Human Ebola virus outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Diseases, 9, 723–728.

Maganga GD, Kapetshi J, Berthet N, Kebela Ilunga B, Kabange F, Mbala Kingebeni P, Mondonge V, Muyembe JJ, Bertherat E, Briard S, Cabore J, Epelboin A, Formenty P, Kobinger G, Gonzalez-Angulo L, Labouba I, Manuguerra JC, Owko-Bele JM, Dye C and Leeroy EM, 2014. Ebola virus disease in the Democratic Republic of Congo. The New England Journal of Medicine, 371, 2083–2091.

Marré S, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Dux A, Kuhl HS, Kabaa M, Regnaut S, Merkel K, Sachse A, Thiesen U, Villanyi L, Boesch C, Dabrowski PW, Radonic A, Nitsche A, Leendertz SA, Petterson S, Becker S, Krahlving V, Couacy-Hymann E, Akoua-Koffi C, Weber N, Schaade L, Fahr J, Borchert M, Gangarten J, Calvignac-Specher and Leendertz FH, 2015. Investigating the zoonotic origin of the West African ebola epidemic. EMBO Molecular Medicine, 7, 17–23.

Martins KA, Jahrling PB, Bavar S and Kuhn JH, 2016. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Review of Vaccines, 15, 1101–1112.

Marzi A, Feldmann H, Geisbert TW and Faizalano D, 2011. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. Journal of Bioterrorism & Biodefense, 5, 2157–2526.

Marzi A, Hanley PW, Haddock E, Martellaro C, Kobinger G and Feldmann H, 2016. Efficacy of vesicular stomatitis virus-ebola virus postexposure treatment in rhesus macaques infected with Ebola virus merokana. The Journal of Infectious Diseases, 214, 360–366.

Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, Christie A, Schroth GP, Gross SM, Davies-Wayne GJ, Shinde SA, Murugan R, Sieh SB, Badiyo M, Fakoli L, Taweh F, De Wet E, van Doremalen N, Munster VJ, Petterson S, Bochet M, Krahlving V, Couacy-Hymann E, Akoua-Koffi C, Weber N, Schaade L, Fahr J, Borchert M, Gangarten J, Calvignac-Specher and Leendertz FH, 2015. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Molecular Medicine, 7, 17–23.

Mathiot CC, Fontenelle D, Georges AJ and Coulanges P, 1989. Antibodies to haemorrhagic fever viruses in the Congo. The New England Journal of Medicine, 373, 2448–2454.

McElrath MJ, De Rosa SC, Frahm N, Cohen KW, Shukarev G, Orzabal N, van Duijnhooven W, Truayers C, Bachmayer N, Splinter D, Samy N, Pau MG, Schuitemaker H, Luhn K, Callendret B, Van Hoof J, Douoguigui M, Ewer K, Angels B, Pollard AJ and Snape MD, 2016. Safety and immunogenicity of novel adenovirus Type 26- and modiﬁed vaccinia ankara-vecobed ebova vaccines: a randomized clinical trial. JAMA, 315, 1610–1623.

Mire CE, Geisbert JB, Agans KN, Deer DJ, Fenton KA and Geisbert TW, 2016. Oral and conjunctival exposure of nonhuman primates to low doses of Ebola makona virus. The Journal of Infectious Diseases, 214, 263–267.
Morvan JM, Deubel V, Gounon P, Nakoue E, Barriere P, Murri S, Perpète O, Selekon B, Coudrier D, Gautier-Hion A, Colyn M and Volekhov V, 1999. Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic. Microbes and Infection, 1, 1193–1201.

Mulangu S, Borchert M, Pawska J, Tshomba A, Afounded A, Kulidri A, Swanepoel R, Muyembe-Tamfum JJ and van der Stuyft P, 2016. High prevalence of IgG antibodies to Ebola virus in the Efe pygmy population in the Watsa region, Democratic Republic of the Congo. BMC Infectious Diseases, 16, 263.

Nakayama E and Saijo M, 2013. Animal models for Ebola and Marburg virus infections. Frontiers in Microbiology, 4, 267.

NIAID (National Institute of Allergy and Infectious Diseases), online. NIAID Emerging Infectious Diseases/Pathogens | NIH: National Institute of Allergy and Infectious Diseases. Available online: https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens [Accessed: 11 October 2016]

NIH (National Institutes of Health), online. Clinical Trials. Available online: https://clinicaltrials.gov/ct2/results?term=ebola&pg=1 [Accessed: 11 October 2016]

Nkoghe D, Kone ML, Yada A and Leroy E, 2011. A limited outbreak of Ebola haemorrhagic fever in Etoumbi, Republic of Congo, 2005. Transactions of the Royal Society of Tropical Medicine and Hygiene, 105, 466–472.

Ogawa H, Miyamoto H, Nakayama E, Yoshida R, Nakamura I, Sawa H, Ishii A, Thomas Y, Nakagawa E, Matsuno K, Kajihara M, Maruyama J, Nao N, Muramatsu M, Kuroda M, Simulundu E, Changula K, Hang’ombe B, Namangala K, Namita A, Kathampi J, Igarashi M, Ito K, Feldmann H, Sugimoto C, Moonga L, Mweene A and Takada A, 2015. Seroseroepidemiological prevalence of multiple species of filoviruses in fruit bats (Eidolon helvum) migrating in Africa. The Journal of Infectious Diseases, 212, 101–108.

OIE (World Organization for Animal Health), online-a. Register of diagnostic kits certified by the OIE as validated as fit for purpose. Available online: http://www.oie.int/our-scientific-expertise/certification-of-diagnostic-tests/the-register-of-diagnostic-tests/ [Accessed: 11 October 2016]

OIE (World Organization for Animal Health), online-b. OIE-Listed diseases 2016. Available online: http://www.oie.int/animal-health-in-the-world/oie-listed-diseases-2016/ [Accessed: 11 October 2016]

Olival KJ and Hayman DT, 2014. Filoviruses in bats: current knowledge and future directions. Viruses, 6, 1759–2416.

Olival KJ, Islam A, Yu M, Anthony SJ, Epstein JH, Khan SA, Khan SU, Cramer G, Wang LF, Lipkin WI, Luby SP and Daszak P, 2013. Ebola virus antibodies in fruit bats, Bangladesh. Emerging Infectious Diseases, 19, 270–273.

Olivero J, Fa JE, Real R, Farrán MA, Márquez AL, Vargas JM, Gonzalez JP, Cunningham AA and Nasi R, 2017. Mammalian biogeography and the Ebola virus in Africa. Mammal Review, 47, 24–37.

Olson SH, Reed P, Cameron KN, Ssebide BJ, Johnson CK, Morse SS, Karesh WB, and Joly DO, 2012. Dead or alive: animal sampling during Ebola hemorrhagic fever outbreaks in humans. Emerging Health Threats Journal, 5, 9134.

Paweska JT, Storm N, Grobbelaar AA, Markotter W, Kemp A and Jansen van Vuren P, 2016. Experimental inoculation of Egyptian fruit bats (Rousettus aegyptiacus) with Ebola virus. Viruses, 8, 29.

Perry DL, Bollinger L and White GL, 2012. The Baboon (Papio spp.) as a model of human Ebola virus infection. Viruses, 4, 2400–2416.

Piercy TJ, Smither SJ, Steward JA, Eastaugh L and Lever MS, 2010. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. Journal of Applied Microbiology, 109, 1531–1539.

Pigott DM, Golding N, Mylne A, Huang Z, Henry AJ, Weiss DJ, Brady OJ, Kraemer MU, Smith DL, Moyes CL, Bhatt S, Gething PW, Horby PW, Bogoch II, Brownstein JS, Mekaru SR, Tatem AJ, Khan K and Hay SI, 2014. Mapping the zoonotic niche of Ebola virus disease in Africa. Elife, 3, e04395.

Poupart X, Delicat A, Rollin PE, Ksiazek TG, Gonzalez JP and Leroy EM, 2007. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. The Journal of Infectious Diseases, 212, 101–108.

Qiu X, Souris M, Towner JS, Rollin PE, Nichol ST, Gonzalez JP and Leroy E, 2009. Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infectious Diseases, 9, 159.

Prescott J, Bushmaker T, Fischer N, Mazgajowicz K, Judson S and Munster VJ, 2015. Postmortem stability of Ebola virus. Emerging Infectious Diseases, 21, 856–859.

Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Stroher U, Feldmann H and Jones SM, 2009. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEOBV GP vaccine stimulates strong Ebola GP-specific immune responses. PLoS ONE, 4, e5547.

Qiu X, Wong G, Auget J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Vesaloc J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L and Kobinger GP, 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature, 514, 47–53.

Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ and Nichols DK, 2011. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes and Infection, 13, 930–936.

Reed PE, Mulangu S, Cameron K, Ndonze AU, Joly D, Bermejo M, Rouquet P, Fabozzi G, Bailey M, Shen Z, Keele BF, Hahn B, Karesh WB and Sullivan NJ, 2014. A new approach for monitoring ebolavirus in wild great apes. PLoS Neglected Tropical Diseases, 8, e3143.
Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Joslyn MD, Kwilas SA, Van Deussen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peal SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RTJ and Thomas SJ, 2017. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. New England Journal of Medicine, 376, 330–341.

Rollin PE, Williams RJ, Bressler DS, Pearson S, Cottingham M, Puacak G, Sanchez A, Trappeier SG, Peters RL, Greer PW, Zaki S, Demarcus T, Hendrickx K, Kelley M, Simpson D, Geisbert TW, Jahrling PB, Peters CJ and Ksiazek TG, 1999. Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. The Journal of Infectious Diseases, 179, 108–114.

Rougeron V, Feldmann H, Grard G, Becker S and Leroy EM, 2015. Ebola and Marburg haemorrhagic fever. Journal of Clinical Virology, 64, 111–119.

Rouquet P, Froment JM, Bermejo M, Kilbourn A, Karesh W, Reed P, Kumulungui B, Yaba P, Delicat A, Rollin PE and Leroy EM, 2005. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001–2003. Emerging Infectious Diseases, 11, 283–290.

Sagripanti JL, Rom AM and Holland LE, 2010. Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces. Archives of Virology, 155, 2035–2039.

Schoder D, Strauss A, Szakmary-Brandle K, Stessl B, Schlager S and Wagner M, 2015. Prevalence of major foodborne pathogens in food confiscated from air passenger luggage. International Journal of Food Microbiology, 209, 3–12.

Schoepf RJ, Rossi CA, Khan SH, Goba A and Fair JN, 2014. Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerging Infectious Diseases, 20, 1176–1182.

Sissoko D, Laouenan C, Folkesson E, M, Schoepp RJ, Rossi CA, Khan SH, Goba A and Fair JN, 2014. Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerging Infectious Diseases, 20, 1176–1182.

Smither SJ, Nelson M, Eastaugh L, Nunez A, Salguero FJ and Lever MS, 2015. Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit. The Journal of Infectious Diseases, 212, 336–345.

Soka MJ, Choi MJ, Baller AH, White S, Rogers E, Purpura LJ, Mahmoud N, Wasunna C, Massaquoi M, Abad N, Kollie J, Dweh S, Bernah PK, Christie A, Ladele V, Subah OC, Pillai S, Mugisha M, Kpaka J, Kowalewski S, German E, Stenger M, Nichol S, Stroher U, Vanderende KE, Zarecki SM, Green HH, Bailey JA, Rollin P, Marston B, Nyenswah TG, Gasasira A, Knust B and Williams D, 2016. Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA survival using spiders. Journal of Virological Methods, 177, 127–138.

Sprenger M and Coulombier D, 2014. Preparedness is crucial for safe care of Ebola patients and to prevent onward transmission in Europe – outbreak control measures are needed at its roots in West Africa. Euro Surveillance: bulletin Européen Sur les Maladies Transmissibles =. European Communicable Disease Bulletin, 19, 20925.

Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicissia A, Cortese R, Koup RA and Sullivan NJ, 2014. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Medicine, 20, 1126–1129.

Stansfield SK, Scribner CL, Kaminski RM, Cairns T, McCormick JB and Johnson KM, 1982. Antibody to Ebola virus in Guinea pig: tandem, Zaire. The Journal of Infectious Diseases, 146, 483–486.

Swamy V and Pinedo-Vasquez M, 2014. Bushmeat harvest in tropical forests: Knowledge base, gaps and research priorities. (Vol. 114). CIFOR.

Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, Rollin PE, Zaki SR and Peters CJ, 1996. Experimental inoculation of plants and animals with Ebola virus. Emerging Infectious Diseases, 2, 321–325.
AHL assessment on Ebola virus disease

Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kiency MP, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Daily L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Kouf RA, Roederer M, Legderwood J, Hill AV, Ballou WR, Sullivan N, Graham B and Levine MM, 2016. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. The Lancet. Infectious Diseases, 16, 31–42.

Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J, Dobo S, Rose A, El-Kattan Y, Taubenheim B, Babu Y and Sheridan WP, 2016. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. Journal of Infection and Public Health, 9, 220–226.

Tracey LE, Regan AK, Armstrong PK, Dowse GK and Effler PV, 2015. EbolaTracks: an automated SMS system for monitoring persons potentially exposed to Ebola virus disease. Euro Surveillance: bulletin Europe sur les Maladies Transmissibles = European Communicable Disease Bulletin, 20, 20999.

Twenhafel NA, Mattix ME, Johnson JC, Robinson CG, Pratt WD, Cashman KA, Wahl-Jensen V, Terry C, Olinger GG, Hensley LE and Honko AN, 2013. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Veterinary Pathology, 50, 514–529.

Twenhafel NA, Shaia CI, Bunton TE, Shamblin JD, Wollen SE, Pitt LM, Sizemore DR, Ogg MM and Johnston SC, 2015. Experimental aerosolized guinea pig-adapted Zaire ebolavirus (variant: Mayinga) causes lethal pneumonia in guinea pigs. Veterinary Pathology, 52, 21–25.

Wahl-Jensen V, Bollinger L, Safronetz D, de Kok-Mercado F, Scott DP and Ebihara H, 2012. Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers. Viruses, 4, 3754–3784.

WB (World bank), online. 7 facts about population in Sub-Saharan Africa. Available online: http://blogs.worldbank.org/africachannel/7-facts-about-population-in-sub-saharan-africa [Accessed: 10 October 2016]

Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G and Kobinger GP, 2012. Transmission of Ebola virus from pigs to non-human primates. Scientific Reports, 2, 811.

WHO (World Health Organization), online-a. Successful Ebola responses in Nigeria, Senegal and Mali. Available online: http://www.who.int/csr/disease/ebola/one-year-report/nigeria/en/ [Accessed: 18 October 2016]

WHO (World Health Organization), online-b. Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa. Available online: http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/ [Accessed: 11 October 2016]

WHO (World Health Organization), online-c. Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola. Available online: http://apps.who.int/iris/bitstream/10665/130596/1/WHO_HIS_SDS_2014.4-eng.pdf?ua=1 [Accessed: 18 October 2016]

WHO (World Health Organization), online-d. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during Outbreaks. Interim Guidance for National Health Authorities and Blood Transfusion Services. Available online: http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/ [Accessed: 18 October 2016]

WHO (World Health Organization), online-e. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola. Available online: http://www.who.int/medicines/ebola-treatment/2015-0218_tables_of_ela.pdf [Accessed: 18 October 2016]

WHO (World Health Organization), online-f. Ebola virus disease. Available online: http://www.who.int/mediacentre/factsheets/fs103/en/ [Accessed: 18 October 2016]

WHO (World Health Organization), online-g. Emergency use assessment and listing procedures for medical products during public health emergencies. Available online: http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/ [Accessed: 18 October 2016]

WHO (World Health Organization), online-h. Use safe burial practice. Available online: http://www.who.int/csr/resources/publications/ebola/whocmsres982sec7-9.pdf [Accessed: 30 November 2016]

WHO (World Health Organization), online-i. Guidance on regulations for the Transport of Infectious Substances 2015-2016. Available online: http://apps.who.int/iris/bitstream/10665/149288/1/WHO_HSE_GCR_2015.2_eng.pdf?ua=1 [Accessed: 18 October 2016]

WHO (World Health Organization), 1978. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bulletin of the World Health Organization, 56, 247–270.

Wittmann TJ, Biek R, Hassanin A, Rouquet P, Reed P, Yaba P, Pourrut X, Real LA, Gonzalez JP and Leroy EM, 2007. Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants. Proceedings of the National Academy of Sciences of the United States of America, 104, 17123–17127.

Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP and Qiu X, 2014. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine, 32, 5722–5729.

Wong G, Qiu X, Richardson JS, Cutts T, Collignon B, Gren J, Aviles J, Embury-Hyatt C and Kobinger GP, 2015. Ebola virus transmission in guinea pigs. Journal of Virology, 89, 1314–1323.

Zheng X, Wong G, Zhao Y, Wang H, He S, Bi Y, Chen W, Jin H, Gai W, Chu D, Cao Z, Wang C, Fan Q, Chi H, Gao Y, Wang T, Feng N, Yan F, Huang G, Zheng Y, Li N, Li Y, Qian J, Zou Y, Kobinger G, Gao GF, Qiu X, Yang S and Xia
X, 2016. Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Scientific Reports, 6, 24179.

Zhu FC, Wurie AH, Hou LH, Liang Q, Li YH, Russell JB, Wu SP, Li JX, Hu YM, Guo Q, Xu WB, Wurie AR, Wang WJ, Zhang Z, Yin WJ, Ghazzawi M, Zhang X, Duan L, Wang JZ and Chen W, 2017. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 389, 621–628.

Zumbrun EE, Abdeltawab NF, Bloomfield HA, Chance TB, Nichols DK, Harrison PE, Kotb M and Nalca A, 2012a. Development of a murine model for aerosolized ebolavirus infection using a panel of recombinant inbred mice. Viruses, 4, 3468–3493.

Zumbrun EE, Bloomfield HA, Dye JM, Hunter TC, Dabisch PA, Garza NL, Bramel NR, Baker RJ, Williams RD, Nichols DK and Nalca A, 2012b. A characterization of aerosolized Sudan virus infection in African green monkeys, cynomolgus macaques, and rhesus macaques. Viruses, 4, 2115–2136.

Abbreviations

AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
CDC Centers for Disease Control and Prevention
CFSPH Center for Food Security and Public Health
CITES Convention on International Trade in Endangered Species of Wild Fauna and Flora
DALY disability-adjusted life year
ECDC European Centre for Disease Control and Prevention
ELISA enzyme-linked immunosorbent assay
EV Ebola virus
EVD Ebola virus disease
Ig immunoglobulin
ICBA Individual and Collective Behavioural Aggregation
IUCN International Union for the Conservation of Nature
MS Member State
NHP non-human primates
OIE World Organization for Animal Health
PCR polymerase chain reaction
ToR Terms of Reference
WHO World Health Organization
YLL years of lives lost